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The 18th International Symposium on Laboratory Automation and Robotics provided presentations on state-of-the-art
developments in laboratory automation and robotics. The symposium programme included papers and posters on all
aspects of the technology. These comprised: managing laboratory automation (drug discovery); bioanalytical analysis;
managing laboratory automation in drug discovery development and QC laboratory; functional genomics strategies and
high throughput screening; advanced integration strategies; method development and global methods transfer;
compound handling and logistics; combinatorial chemistry and automated synthesis; high throughput LC-MS-MS;
increasing eæ ciency in dissolution testing; lead optimization; strategies for UHTS; increasing throughput for ADME
toxicology; data management/data handling and bioinformatics; using contract laboratories to increase productivity;
assay miniaturization; process optimization; compliance and automationÐ the regulatory perspective; novel high
throughput screening technologies; compliance and automationÐ the industry perspective. Several discussion sessions
were included and activated, and provided interactive communication on a wider range of subjects.
Although the programme was very comprehensive, the Symposium was designed to provide time for both formal and
informal exchange of information. The technical presentations were organized into concurrent sessions with grouped
papers on related topics.
Abstracts for each paper and each poster are included here. Full presentations of several of these papers will appear in
later editions of this journal.
Genomics and the new era of drug discovery: a
Wall Street perspective
E. James Streator, III, Director of Healthcare Investment
Banking and Partner, Thomas Weisel Partners, NY
The new era of drug discovery is revolutionary, it is
complicated and it is just beginning. Wall Street’ s
enthusiasm for and lack of understanding of industry
participants has been demonstrated by its investment
history. In the last twelve months, investors bid genomics
and drug discovery stocks up an average of 400%, then
proceeded to cut valuations in half, only to bid prices up
again.
As a whole, genomics companies trade at a premium to
the tools companies at approximately 30£ 2001 revenue
estimates. We believe Wall Street grants genomics com-
panies a premium because it perceives them as owning
the data, and thus having a tie to the enormous potential
upside. We expect that revenue growth, new technology
breakthroughs, and new biological discoveries will drive
valuations for these companies over the foreseeable
future.
Drug discovery tools and instruments companies trade at
a wide range of multiples, from microarray companies
trading at 40£ 2001 revenue to consumables and equip-
ment companies trading at 15± 20£. As ` picks and
shovels’ infrastructure plays, investors look for revenue
visibility and recurring revenue. In addition, the market
does not fully appreciate the relationship between instru-
ments and related technology and Moore’ s law (the
doubling of processing speeds every 18 months). We
expect valuations to be driven by revenue growth and
collaborations for the foreseeable future.
Productivity and drug discovery: the Genzyme
small molecule experience
Frederik Vinick, Senior Vice President of Drug Discovery,
Genzyme Corporation, Cambridge, MA
Drug Discovery has always been a challenging, diæ cult,
expensive proposition, appropriately characterized as
high risk/high return. The pharmaceutical industry has
a distinctly diæ cult time generating its product, new
drugs, in a timely, predictable, cost-eå ective manner.
Many factors, a good number of them intrinsic to the
complex science of novel drug discovery, contribute to
this problem. As the industry has moved from the era of
` me, too’ imitative products to the current age of
genomics, new targets and a heavy emphasis on poorly
treated diseases, the challenge at hand (and the attend-
ant risk and uncertainty) has become even more severe.
Thus, at a time when we have access to many powerful
new technologies which, in principle, oå er us new, more
eå ective solutions to the daunting problems we must
solve, it is worthwhile, in fact necessary, for us to
consider, prudently and thoughtfully, the best uses of
these tools. Automation, miniturization, surrogate in vitro
models, less in vivo testingÐ all of these notions are at face
value virtually unquestionable, incontrovertible major
steps in the right direction towards more productive drug
discovery. However, we have to guard against the use of
these clever tools in ways that actually create more work
and cost.
In this talk, we describe the Genzyme approach to drug
discovery, a hybrid of methods, new and old, which seeks
to minimize risk/cost and maximize the output of drug
candidates (novel substances which are safe and eæ ca-
cious in animal models of disease). We will illustrate our
Journal of Automated Methods & Management in Chemistry, Vol. 23, No. 1 (January–February 2001) pp. 1–37
Journal of Automated Methods & Management in Chemistry ISSN 1463± 9246 print/ISSN 1464± 5068 online # 2001 ISLAR
http://www.tandf.co.uk/journals
DOI: 10.1080/14639240010040348
1strategy with data from several actual examples. We will
also propose a research process which we believe illus-
trates a highly eæ cient use of modern technologies.
Modern HTS: infrastructure and work￿ ow versus
technology and science
Melvin Reichman, Dupont Pharmaceuticals, Wilmington, DE
The advances in HTS technologies over the past decade
have been impressive; however, raw HTS remains a
minor component (<3%, by time) of the typical Dis-
covery project life-cycle. If we postulate the view that
drug screening in Pharma represents a manufacturing
process wherein the deliverables are bona ¢de development
candidates, rate-limited steps can be proactively identi-
® ed and mitigated. The talk will review by example the
role of project management in the overarching disciplines
comprising the extended drug screening process. Central-
ized HTS, compound handling, quality control and
assurance and information management are presented
as core components of the modern drug discovery infra-
structure that enable the eæ cient execution of hit-to-lead
operations through to drug Development.
Accelerated lead identi￿ cation: a result of process
industrialization
Berta Strulovici, Merck & Co., North Wales, PA
The industrialized era in pharmaceutical discovery will
require creativity and innovation in each component of
the drug discovery machinery. Three years ago, Merck
Research Laboratory formed a dedicated HTS unit, to
screen organic compound and natural product libraries
for new therapeutic lead candidates. This is a stand-alone
facility that integrates assay development, compound
management, ultra-fast robotics, screen miniturization
technologies, and complex data management systems
linked by computerized control networks. Our approach
to HTS is based on intact cell and biochemical systems
using the power of robotics capable to operate 24 hours/
day, for weeks at a time. I will present speci® c examples
where our approach of combining novel assay tech-
nologies with innovations in automation and software
applications proved fruitful, as attested by the identi® ca-
tion of lead candidates in several new therapeutic areas in
record time.
Fostering innovation in the corporate laboratory
John Babiak, Pharmacopeia, Princeton, NJ
Opportunities for technological innovation in the lab
continue to appear at a rapid pace. Screens miniturized
to as small as 1ml have been performed on the scale of
over 200,000 wells. Novel, homogeneous formats are
becoming available that can simplify many assay types.
Automation and scheduling software continue to im-
prove both speed and ¯ exibility of screening systems. At
a super® cial level it appears that all things are possible
with suæ cient resources and time to implement the
correct combination of technologies. One question to
consider, therefore, is what should the process be to
support innovations within the corporate laboratory.
No laboratory can evaluate and implement every tech-
nical tool that is available. Development of new tech-
nologies in the corporate lab setting, such as in high
throughout screening (HTS), requires the balancing of
multiple factors:
. Productivity versus innovation
. Established products versus high-risk beta (or
alpha) testing
. Buy versus build versus co-develop
. Big solutions versus small solutions
. Focus on a few specialties versus create a broad
portfolio of capabilities
. Involvement of staå in technology development ver-
sus screening
All these issues are in¯ uenced by the corporate environ-
ment (and goals), staæ ng, resources and history. There-
fore, it is important to create an atmosphere where novel
ideas are invited and discussed, some are explored, the
most valuable are implemented and mistakes are educa-
tional.
Managing the evolution of screening: from decen-
tralized HTS to centralized UHTS
Mary Jo Wildey, The R. W. Johnson Pharmaceutical Research
Institute, Raritan, NJ
The Drug Discovery lead identi® cation process has been
evolutionary, with goals directed toward shortening the
time needed to develop new chemical entities. Tradition-
ally, many organizations have chosen decentralized
approaches to screening. This approach utilizes personnel
resources from the research teams to perform the screens
and resources from a central automation team to provide
programming, validation, and data processing support.
Due to hardware and assay format technology advances,
many organizations have experienced signi® cant in-
creases in throughput capabilities. In many cases, these
increased capabilities are the basis for the change to
centralized screening groups where the automation team
performs the bulk of the screening operation with limited
assistance from the research teams.
We shall discuss the practical aspects of making the
change from decentralized to centralized screening plat-
forms. Topics including hardware and software impacts,
system support, and impact on personnel will be ad-
dressed. We will also discuss ideas on diminishing the
risks that accompany technology shifts and the practical
management of this process.
Semi-automated sample preparation 96-well for-
mat extractions
Anita Shen, Huong Mai, Min Chang, Hope Skriba, Qin Ji, Ray
Wieboldt, Daniel Daszkowski and Tawakol El-Shourbagy,
Abbott Labs, Abbott Park, IL
Sample preparation has always been a time and labor
consuming and error-prone step in the work¯ ow of a
bioanalytical laboratory. Since the development of user
friendly LC/MS and its acceptance as a HPLC detector,
sample preparation has become the bottleneck of the
whole process. In order to improve the quality and
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manual solid phase extraction and liquid-liquid extrac-
tion, automated instruments were introduced. The ® rst
generation laboratory robots such as Zymark Zymate,
Perkin-Elmer MasterLab and Waters MilliLab are serial
instruments. Although advanced users may program
some ® rst generation robots to do several activities in
parallel, most of the activities have been performed in
series. As a result of this serial nature, the throughput of
the robotic assay was about 6 to 12 minutes per sample.
To increase the throughput, solid phase extractions were
performed using individual workstation or workstation
banks, then the robotic arm was freed up to perform
other tasks. Another approach is to perform the steps in
large array formats such as the 96-well microtitre plate.
In this presentation, the Hamilton Micro Lab AT was
used as a re-formatting workstation, which transfers the
plasma samples from clinical tubes to 96-well plates. The
Micro Lab also added the internal standard, treatment
reagents for solid phase extraction (SPE) and organic
solvents for liquid-liquid extraction (LLE). The advan-
tage of the Hamilton is its ability to pipette 12 samples in
each cycle reliably. For LLE, the 96 well plate was sealed
with a polyethylene ® lm by heat (Comb sealer from
Marsh Biomedical). Extraction was performed by shaking,
centrifuging and ® nally, phase separation with the
Hamilton Micro Lab. For SPE, the treated sample in
96-well plates was transferred to SPE workstation such as
Beckman Biomek 2000 or Tom Tech Quadra for further
processing. Using those workstations, an analyst was able
to extract four 96-well plates and perform the LC/MS
analysis in one workday with high reproducibility.
Several semi-automated, 96-well format LLE or SPE,
LC/MS assays were validated and used to support
clinical trials.
Collecting sample weight data on various liquid
handling robots
Jimmy Bruner, Larry Birkemo, Kelly Jordan, Glenn Smith,
and James Ormand, Glaxo Wellcome Inc., Research Triangle
Park, NC
Liquid-handling platforms often do not provide a mech-
anism for collecting weight data needed for instrument
quali® cation and sample transfer con® rmation. This
paper discusses the development, implementation, and
application of a system that facilitates liquid-handling
con® rmation required for Good Laboratory Practice
(GLP) compliance and provides an avenue to track
amount of sample transferred for extraction.
The Balance Data Collector (BDC) system was designed
as a ¯ exible generic balance tool to be used with Tecan
Gemini
# and Packard WinPrep
1 software. The BDC
system provides a user interface for balance con® gura-
tion, a pointer to a ® le for storing weight data, and an
external interface through command line arguments.
BDC is currently used for instrument quali® cation and
sample collection in bioanalytical applications. Instru-
ment quali® cation includes re® ning instrument liquid
classes and verifying pipetting accuracy and precision.
For bioanalytical applications using 96-well plates, BDC
collects individual aliquot weights of samples transferred
during an assay.
The BDC system gives us the capability to control a




of liquid-handling platforms and BDC reduces the time
the scientist must spend recording weight data needed for
GLP compliance and can be used to increase accuracy of
calculated sample concentrations.
Laboratory automation strategies for method de-
velopment and sample analysis
Roger Coe, JD Hulse and JW Lee, MDS Harris Laboratories,
Inc.
Purpose. The routine use of LC/MS/MS has shifted the
rate-limiting step for high-throughput sample analysis
from instrument to sample processing. Solid-phase ex-
traction (SPE) in the 96-well format allows fast sample
extraction from biological matrices. Our purpose was to
work out a strategy exploiting the advantages of two
diå erent types of SPE automation: The ¯ exible program-
ming of Zymark RapidTrace
1 was used for eå ective
method development, and the method is then adapted
to Tomtec Quadra-96
1 for high sample throughput.
Additional automation such as liquid-handling robots
(Tecan Genesis RSP) and barcode reading supplements
the 96-well assay for fast sample turnaround.
Methods. The RapidTrace
1 workstation was pro-
grammed to conduct multiple experiments to screen
SPE sorbents for the target analytes in non-matrix sol-
utions. Conditions for the desirable interaction of the
analytes with the sorbent were investigated and selected.
The SPE rinsing and eluting parameters were tested
using diå erent combinations of solvents to wash un-
wanted components away and optimally recover the
analytes from the biological matrix. The chosen method
was adapted to 96-well on the Quadra-96
1, which allows
all 96 samples to be processed simultaneously. Previous
validated methods with SPE cartridges were also opti-
mised using the RapidTrace
1 and the methods trans-
ferred to the 96-well format on the Quadra 96
1.
Results. The outlined strategy was applied successfully
to develop assays for several compounds in a short period
of time. Examples are provided for a synthetic narcotic,
basic drugs, and progestins. Previous cartridge SPE
methods of tamoxifen and ¢9-tetrahydrocannabinol
and its hydroxylated metabolite were transferred to the
96-format. The typical method development time was
less than 5 days. Typical sample processing time for 96
samples was 15 to 50min. Inter-plate variability was
tested to extend from single to multiple plates within a
batch run. When samples were aliquoted by the Tecan
Genesis
1, at least six plates could be extracted in one
day.
Conclusion. A rational and eæ cient approach for
method development and validation using two diå erent
automated SPE systems was eå ective in providing fast
turnaround time to support the fast paced LC/MS
instrument.
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3384-well solid phase extraction: strategies and
limitations
Geo¡rey Rule, Advanced BioAnalytical Services, Ithaca, NY
Solid-phase extraction (SPE) has been widely adopted as
a sample preparation technique since its introduction in
the 1970s. Along with liquid-liquid extraction and ` on-
line’ sample preparation techniques it ® lls a substantial
portion of the sample preparation needs of high-through-
put laboratories. Since the introduction of 96-well SPE
over four years ago, more and more laboratories with
high-throughput requirements have moved to this
format as a means of increasing sample preparation
productivity.
Recently, we have demonstrated SPE in a higher density,
384-well format for the drug methotrexate and its 7-
hydroxy metabolite in both human urine and plasma.
The method makes use of 5mm C18 particles entrapped
within a glass ® ber disk and a semi-automated robotic
workstation. The ability to prepare and analyze 384
samples as a single analytical run has been demonstrated
with good precision and accuracy. A second method,
previously developed and validated in 96-well SPE
format for an undisclosed drug, has also been modi® ed
for a 384-well format cross-validation. The results of these
investigations will be presented along with discussion on
the practical aspects (general strategy, instrumentation,
and limitations) of 384-well sample preparation and its
potential for increasing instrument utilization and reduc-
ing data turnaround times.
New century...new applications for automation
in pharmaceutical analysis
Stephen Scypinski, Ronnie McDowell, Ron Muenz, John Troisi,
Adam Fermier, Analytical Chemistry Research & Development,
The R. W. Johnson Pharmaceutical Research Institute, Raritan,
NJ
The advent of the new millennium brings new challenges
and opportunities for automation in the pharmaceutical
analysis laboratory. While utilization of workstations for
automated assay, content uniformity and dissolution in
the analytical laboratory continues to dominate the
landscape of pharmaceutical analytical chemistry, other
automation arenas are beginning to emerge.
The rapid expansion of drug discovery eå orts in most
pharmaceutical companies, coupled with the utilization
of high throughput screening and combinatorial chem-
istry has increased the demand for analytical data at a
very early stage in the drug development process. The
desire to choose the proper development candidate is
based not only on preclinical data but also physiochem-
ical information. The large amount of compounds that
must be screened for such characteristics as pH/solubility
pro® le, octanol-water partition coeæ cient and other
preformulation parameters generates a great deal of
analytical work that must be performed. To complicate
matters, one is generally sample-limited at this phase of
development.
We have begun to explore options for automation of such
early phase preformulation activities in our laboratory to
provide better and more timely support for our cus-
tomers. By utilizing the ¯ exibility of general laboratory
automation and the ability of drug discovery to work
with small quantities of sample, we have constructed
systems that perform analyses and measurements for
early drug development candidate screening. In addition
to conventional laboratory automation, we have also
explored the route of ` parallel processing’ and miniatur-
ization as another means of obtaining more data on a
limited amount of sample more quickly. Examples of the
various systems constructed and used in our laboratory
and their impact on drug development will be discussed.
Learnings for introducing automated dissolution,
automated HPLC & new technology
Jay Makwana, Boots Healthcare, Nottingham, UK
Having introduced new technology into drug product
development laboratories to deal with demands for
increasing workload and improvements in pace of analy-
tical work, I will share our learnings. In this presentation,
I will cover the introduction of automated dissolution,
automated HPLC, capillary electrophoresis and a net-
worked data handling system.
I will also reveal some accounts of the softer challenges of
getting buy-in from the staå , converting high scepticism
to love in some cases. Other key steps of evaluation,
preparing purchase proposals, implementation planning,
validation, resource selection and importance of enthu-
siastic champions, continuous improvement and project
management will also be addressed. A ¯ ow chart of a
recommended process is one of the key outcomes to help
with introduction of new technology and passionately
pursue success.
A practical strategy for utilizing standard auto-
mation technology across multiple components
Michael Rutherford, Eli Lilly and Company, Lilly Corporate
Center, Indianapolis, IN
As the pharmaceutical industry continues to change,
more emphasis is being placed on the identi® cation and
development of new and innovative compounds and
products. To support the rapid development and in-
creased number of these new chemical entities (NCE’ s),
utilization of laboratory automation in the product
development and launch process is becoming increasingly
important to support ` Speed to Market’ initiatives. While
utilizing laboratory automation can provide signi® cant
bene® ts, it is also important to consider standardizing
that technology. Standardization of automation tech-
nology and platforms across the various components
involved in the process can be very bene® cial by provid-
ing increased capacity, better resource utilization, im-
proved quality of results across the organization, detailed
documentation and audit trials, and easier method
transfer.
Over the last decade, laboratory automation has been
utilized eå ectively by Analytical Development and
Quality Control at numerous sites throughout Eli Lilly
and Company through the implementation of a variety of
automated solutions and technology to address speci® c
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4needs. Many of these systems were developed ` in-house’
and/or were custom applications, resulting in some
replication and standardization across various compon-
ents. However, as many of these solutions have become
older and support resources have changed, more empha-
sis is being placed on purchasing ` oå -the-shelf’ solutions.
Asthese automated systems are being replaced,standardi-
zation of automation technology and platforms are also
being considered. To initiate this strategy, Analytical
Development and Quality Control in Indianapolis have
begun to develop and implement several standard auto-
mated solutions across their organizations with initial
emphasis on solid dosage form testing. The strategy,
technology, bene® ts, learning points and experiences,
current project status, and future plans will be discussed
during this presentation.
Delivering a highly automated drug product lab-
oratory—the importance of system integration
standards
Perry Hailey, P¢zer Central Research, Sandwich, UK
Identi￿ cation of cytokines and hormones induci-
ble anti-apoptotoic genes by microarrays
Grace Wong, Serono Reproductive Biology Institute, Randolph,
MA
Design and development of a novel arraying
machine
Steven Frosdick, Radius Biosciences, Med¢eld, MA
Microarrays consist of spots of material aligned on a
regular grid pattern. Typically these spots have a dia-
meter of ¹200± 700 mm and are placed onto ¯ at substrates
at a spot-spot distance of 2± 3£ the spot diameter. Such
arrays of spots have increasing applications in the drug
discovery eå ort. For example, spots of DNA can be used
to determine the modulation of genes in diseased vs
normal tissue, or arrays of chemical compounds can be
used to screen for interactions between these moieties and
receptors or enzyme targets.
A machine will be described that allows for arrays to be
generated on a variety of substrates. The latter can
include glass slides or nylon membranes. The novel
design (patent pending) allows for a high substrate
capacity while maintaining a footprint small enough to
® t on a lab bench. Other features which allow for the
rapid generation of arrays will be discussed as well as
features which allow for more consistent spot morphol-
ogy. The machine has a molecular design to allow it to be
used as a personal spotter or upgraded as a high volume
production machine. This common platform ensures
reduced cost without compromising performance. Intui-
tive software enables arrays to be made from either 96-
well of 384-well source plates. The importance of these
design features will be discussed.
Process management software for MicroArray
gridding
Frances Stewart, C. Teall, B. Gillespie, SmithKline Beecham
Pharmaceuticals
Use of MicroArrays for examination of diå erential gene
expression across tissues and treatments has dramatically
increased over the last 2 years. Increasing data volumes
have created a bottleneck in the process, namely, sample
tracking and data management. Development of a fully
functional process management software system posed
several challenges to informatics groups at SB. Funda-
mental requirements included:
. Integration with evolving clone and tissue registra-
tion databases
. Maintenance of synchronous data sources involving
multiple validations of data integrity
. Integration with internal and external image analy-
sis software
. Integration with internal and external data quality
software
. Integration with multiple robotics platforms
. Tracking plate lineage necessitated by clone and
control sample re-positioning within slides
. Ability to easily incorporate or change multiple
plates to slide mapping schemes for spotting
The SB Cheminformatics group developed a process
management application, MAGNET, to track samples
and data for gridding experiments that provided the
functionality above for open dimensional plates and
slides. Analyzed and normalized expression data pub-
lished to our proprietary gene expression database are
linked to experimental ancestry attributes tracked in
MAGNET. The architecture and software tools used to
build our system are discussed and a short demo of
current functionality will be included.
High throughput functional genomics
Henry Long, Aventis Pharmaceuticals, Cambridge, MA
With massive advances in genomics technology in the
past few years, genes are being discovered far faster than
the functions of the proteins for which they encode can be
characterized. This is rapidly becoming a key bottleneck
in target identi® cation. We will discuss how automation
technologies assist Aventis scientists in addressing these
concerns. High throughput DNA puri® cation is necessary
for many processes and vendors have been slow to
develop ` genomics scale’ , low cost solutions. A novel
magnetic bead based approach will be described that
fully automates DNA minipreps; it has been in produc-
tion at the Cambridge Genomics Center since January
2000. A signi® cant hindrance to functional studies is the
time-consuming restriction enzyme digest and ligation
process required for transferring a target gene into each
diå erent expression vector. Determining gene function
can require numerous functional studies, each using a
diå erent expression vector, also optimizing protein pro-
duction can require trying multiple vectors. Recently,
several cloning systems have appeared on the market that
substantially reduce the amount of eå ort involved, and,
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automation. We will describe our experiences with the
GatewayTM System from Life Technologies and the
automation involved in setting up a high throughput
pipeline.
Maximizing the bene￿ ts of automation tech-
nologies in the world of high throughput screening
Barbara Hynd, Proctor and Gamble Pharmaceutics, Cincinnati,
OH
The ® eld of throughput screening would not exist as we
know it without the bene® ts provided by automation.
The challenge to all practitioners of the science is how to
utilize the technology in such a way as to extract the
maximum bene® t from existing equipment and processes
without compromising speed and accuracy, or falling
behind in the continuing technological advance. Main-
taining this balance as well as the balance between
innovation and ` manufacturing’ processes is challenging
for all HTS groups and is becoming more so in the
current climate of speed, reducing costs and scarcity of
trained personnel.
During this presentation some of the creative uses of
automation technology will be outlined using practical
examples of the diå ering approaches taken by individual
screening groups.
Utilization of peptides as surrogate ligands in high
throughput screening
Dale Christensen, Novalon Pharmaceutical Corp., Durham, NC
Peptides that bind with high aæ nity to drug targets can
be isolated from phase display libraries. If these peptides
bind to the target protein at sites that are critical for
biological function they could be used as surrogate
ligands in a simple ligand binding-type assay for HTS.
To test this hypothesis, we have performed extensive
testing to determine whether the aæ nity selected peptides
bind at biologically relevant sites on enzymes and other
classes drug targets. These peptides bind to biologically
relevant sites in the majority of cases tested to date and
have been shown to inhibit enzyme function and critical
protein:protein interactions. Further, these peptides can
be used as surrogate ligands to detect small molecule
inhibitors of these targets. We have utilized these peptides
to develop HTS assays that can be run with lumines-
cence, time-resolved ¯ uorescence (TRF), ¯ uorescence
polarization (FP), ¯ uorescence resonance energy transfer
(FRET), and scintillation proximity (SPA) detection.
The results of our validation data and our screening
eå orts will be presented.
The di´ erence between vintage and antiquated:
the use of kinetic assays for HTS at vertex
Mark Namchuk, Vertex, Cambridge, MA
Kinetic assays (spectrophotometric or ¯ uorescence) have
long been the method of choice for characterization of
enzymes and enzyme inhibitors. This is because kinetic
assays are less susceptible to artefacts and provide more
precise estimates of the rates of reaction than the
equivalent end point assay. However, kinetic readouts
are not widely used in HTS, mainly due to problems with
protein consumption and low throughput. To address
these issues we have developed a fully automated 384
assay, run on a Zymark platform ® tted with a pair of
Hypertask quadrant positioners and a Biorad Ultramark
UV/Vis plate reader. Data obtained with the upgraded
system is of equivalent quality to its 96 well predecessor
and when fully operational will provide 4 x the through-
put of the original system (¹25,000 data point/day). Test
data obtained with JNK-3 highlights the main assay
development issue with 384 kinetic data, which is mixing
artefacts. Now that the format is validated, it continues to
provide the advantages we observed with 96 well kinetic
screening.
. It is the method of choice with proteins whose sub-
strates do not easily lend themselves to labelling.
. Very short assay development times (usually 2
weeks from receipt of protein to HTS run).
. High data quality provides excellent follow-up rates
(usually >50%).
. Superior starting points for both combinatorial
chemistry and modelling.
Examples of these data from Vertex programs will be
highlighted.
Use of IDE RAID level I (mirroring) for maximum
data integrity on a Zymark Zymate system
Richard Spann, Berlex Biosciences, Richmond, CA
The Zymark System V architecture makes use of a
standard IBM compatible computer (PC) for certain
functions. One aspect of the PC to System V controller
interface is data acquisition and storage.
Certain automated procedures require a repository for
data that is generated during the course of the run. The
source can be analytical instrumentation or a database at
a network location. Depending on the volume of data,
the ¯ oppy disk drive built into the Zymark controller
may not be of suæ cient capacity to serve as a target for
data storage.
Because of the Windows based Zymate Utilities, any
drive available from Windows can be accessed by the
System V controller for writing data ® les. Sending across
a network, however, carries the risk of an interruption in
network service. The most reliable target is a hard drive
installed in the interface PC. Nowadays, large capacity
hard disk drives can be obtained at very reasonable
prices.
To protect against data losses due to power failures, disk
corruption and mechanical failure, regular backups of
the desired drives are routinely performed. Unfortu-
nately, in the event of a data loss, changes made to the
faculty disk after the last backup will not be recoverable.
By implementing redundancy into the data storage
device, the incidence of data loss can be reduced to 0%.
The interface PC currently installed on the Zymark
Zymate XP system in my laboratory was ® tted with an
IDE RAID level 1 (mirroring) adapter. An IDE solution
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than SCSI and fast enough for the applications in use at
my site. The RAID adapter will work with ANY pair of
IDE drivesÐ even of diå ering capacities. There is no
performance hit since special software drivers are not
necessary. Both master and slave disks can be mirrored
from the same adapter if desired.
In combination with regularly scheduled backups of the
mirrored drives, there should never be a loss of informa-
tion. Since the chance of both drives in the pair failing at
the same time are remote, data collection during the
automated run will not be interrupted. If a problem with
one of the mirrored disks develops, the adapter activates
an audible alert so that the operator can install a new
disk and rebuild the mirror using the good drive.
The design of ￿ exible workstation control
software
Claude Dufresne and Miguel Maccio, Merck Research Labora-
tories, Rahway, NJ
Commercial workstations are usually controlled by a
software application that was created by the manufac-
turer of the workstation. Depending on the features of the
application, integrating the workstation into a robotic
environment, or simply integrating its operation with
existing databases, can be diæ cult. The iterative process
of going back to the manufacturer for software modi® ca-
tions is neither satisfying nor necessarily timely.
Facing issues of robot integration, database integration,
and even workstation operation, we decided to create an
in-house workstation control software application. The
application replaces the manufacturer-provided front-
end control software altogether. The design of the soft-
ware application and how it was implemented on a
Bohdan Workstation will be presented.
Personal automation: a robot on every bench
James Gill II, Department of Research Technology, Glaxo-
Wellcome, Research Triangle Park, NC and Department of
Molecular Sciences, GlaxoWellcome Medicines Research Center,
Stevenage, Hertfordshire, UK
During the early 1980s computers broke out of the
computer centers and onto the desktop. Today we have
a spectrum of computing options from desktops for
routine tasks to supercomputers for computationally
intensive tasks. In a similar way, increasing familiarity
with automation and the decreasing complexity of many
assays have allowed robots to escape the automation suite
where they are providing automation for the average
drug discovery scientist. Hopefully, as with PC’ s, auto-
mation will develop that is scaleable so that bench top
systems will handle some assays and the uHTS sytems
will handle the automation intense applications.
Our group has been developing simple ` personal’
robotics, which are inexpensive and ¯ exible enough to
justify wide scale distribution. In addition we feel that
these small systems allow construction of dedicated robots
for simple tasks, assays platforms and even portions of
assays on larger robots. These systems are based on the
Zymark Twister and typically consist of a Twister, a
liquid dispenser and a reader. Systems have so far been
developed to support measurement of solubility, melano-
phore screening, general enzyme screening, general re-
ceptor screening and quality control measurement. These
systems have run 500K HTS campaigns successfully.
In order to insure the accessibility of the systems to the
average scientist we had to insure that inexpensive and
simple software was available and so we developed
Scrippy. Scrippy is a multi-tiered programming environ-
ment. In one tier Scrippy presents a simple interface
which enables the scientist to sequence operations be-
tween the instruments by dragging and dropping com-
mands. However, more advanced users can write in a
scripting language and develop complex commands
which can then be dragged and dropped.
The increasing diversity in robot ` style’ has placed a
serious demand on automation support staå to provide
solutions for a broad portfolio of automation systems. We
have therefore tried to insure that the bench top systems
are ` scalable’ . We are hopeful that the systems will deal
with larger numbers by being replicated. Automation
intensive tasks would then be run on similar instruments
and with the same software drivers on large uHTS
systems thus providing a seamless automation environ-
ment.
Practical aspects of developing automated
methods for solid dosage formulations
Alger Salt, Glaxo Wellcome Inc., Pharmaceutical Development,
Research Triangle Park, NC
Chemical analysis of pharmaceutical dosage forms is an
essential part of assuring product quality. Two common
analytical tests for solid dosage forms are the determina-
tion of drug content and impurities associated with a
batch of product and assessment of the dosage uniformity
of individual units. For chemical analysis of solid dosage
formulations these tests often employ shaking, sonicating,
and/or homogenizing techniques to disperse the tablet
and extract the drug into a suitable solvent. In this
presentation, results obtained from a set of experiments
designed to evaluate the eå ect of energy transfer through
parameters such as homogenizer speeds, sonication times,
etc will be used to compare these extraction techniques.
Useful tips and guidance (derived from years of experi-
ence with the Zymark TPWII tablet processing work-
station) for developing and validating automated
methods will also be presented.
Enhancing the automated method technology
transfer process
Timothy Diehl, Lillian Vazquez, Angelica Chevere, Quality
Assurance Department, Janssen Pharmaceutica, Titusville NJ
The technology transfer process for analytical methods
can be very challenging for Quality Assurance labora-
tories. Failures in the analytical method transfer process
can hold up the implementation of critical testing at a
new production site, or delay the start of a stability study
needed for approval of a product. In the increasingly
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ing, transfer delays cost money. The need for an analy-
tical method transfer to go smoothly and meet the critical
path established by launch teams is more important than
ever before. Transfer delays or failures are caused by
many diå erent variables. A few of the problems encoun-
tered in methods that are not rugged, are incomplete
sample preparation descriptions, instrumentation limita-
tions and training.
In an eå ort to create analytical methods that satisfy both
submission requirements and end user needs in a Quality
Control environment, some laboratories have tried co-
development. However, co-development has not been
successful at dealing with all of the roadblocks for smooth
technology transfer. In this presentation a well-de® ned
process will be described that brings laboratories together
in technology transfer. A procedure that enables the end
user an opportunity to provide input into method
development prior to validation will be discussed.
Transfer of automated methods within a pharma-
ceutical research & development environment
Ronnie McDowell, Ronald Muenz, John Troisi, Stephen
Scypinski, Analytical Chemistry Research & Development, The
R. W. JohnsonöPharmaceutical Research Institute, Raritan,
NJ
The transfer of automated methods to pharmaceutical
quality control laboratories has become a fairly routine
process. With the advent of the ` workstation’ types of
automated instrumentation, the transfer may only re-
quire electronically installing the new method from a
3.5 00 ¯ oppy disc. However, transfer of an automated
method into a research laboratory or a contract labora-
tory proves to be a bit more involved. In these types of
transfers the automation equipment itself, which was
used to develop the method, may have to be transferred
to the receiving laboratory. If not, new equipment may
have to be purchased, installed and quali® ed. Afterwards
SOPs are written and the analysts are trained in the use
of the new equipment. Once the transfer process has
begun any changes in the method requested by the
receiving lab have to be addressed. This presentation
will discuss the steps involved in this type of method
transfer to a research stability laboratory.
A new concept for the on-line storage of sample
plates, integrated with plate preparation for high-
throughput screening and ‘Cherry-Picking'
Jacques van den Broek, Will Kuijpers and Thijs de Boer, NV
Oragon, Oss, The Netherlands; and Jonathan Connick, Organon
Laboratories, Newhouse, UK
Recently Oranon installed automated screening and
plate preparation systems for its research facilities in
Oss (The Netherlands) and Newhouse (UK). These
robotic systems have been developed in close collabora-
tion between Organon and Scitec Laboratory Automa-
tion (Lausanne, Switzerland).
Each of the systems consists of three linear track robots,
one of which performs the screening process using
standard peripherals. The other two robots take case of
the plate preparation and ` cherry-picking’ procedures.
To this end, copies of our total mother plate collection
are stored under controlled conditions in Scitec plate
stackers (AutoStack) that can be addressed by one of the
two robots. The system is designed in such a way that the
loading and refreshment of the on-line storage, screening-
plate preparation, and ` cherry-picking’ can be executed
automatically in 24 hours operation. A more detailed
design of the system and the rationale behind it will be
further disclosed.
High throughput extraction and fractionation of
samples using Zymate robot and dionex acceler-
ated solvent extractor
Ramasamy Tamilarasan, Paul Morabito, and Jon Zieman, The
Dow Chemical Company, Midland, MI, Ted Weglarz, Dow
AgroSciences, Indianapolis, IN, Paul Hazelwood, The Dow
Chemical Company, Sarnia, Ontario, Canada, And, William
Gee, The Dow Chemical Company, Freeport, TX
Automated robotics systems were developed and imple-
mented in Dow AgroSciences (DAS), Indianapolis, to
generate 400 sample extracts per day and separate each
sample extract into 3 fractions. The extraction systems
are based on Zymate XP Robot and the samples are
extracted in a Dionex accelerated solvent extractor
(ASE). Each extraction system includes two ASE and
generates 200 sample extracts per day. Two diå erent
types of fractionation systems were developed based on
the need and availability of automation peripherals.
Finally, a fractionation system was developed based on
Zymate XP and BenchMate robots to fractionate 100
sample extracts per day by performing liquid-liquid
extractions. The extracts are then transferred into 2mL
glass vials for analysis. This system was used for devel-
oping and optimizing the extraction, fractionation and
analysis procedures. In order to maximize the through-
put and minimize the number of systems needed, another
fractionation system was developed based on Hamilton
MPH-96 workstation to fractionate 96 samples at a time
in a titre plate by performing liquid-liquid extractions.
The sample extracts are then transferred into three 96-
well titre plates for analysis. The original sample extracts
are transferred into the 96-well titre plate for fractiona-
tion by using a TECAN MiniPrep-50 in the extraction
system. Barcode labels are used on extraction cartridges,
glass vials, and titre plates to track the sample informa-
tion. Sample preparation data are automatically trans-
ferred to a dedicated LIMS system.
Reformatting equipment for various HTS plat-
forms
Thomas James Hatcher, Pharmacopeia, Inc., Princeton, NJ
Recent advances in high-throughput screening have
necessitated the development of instrumentation capable
of handling multiple microtitre plate formats on the same
platform. This includes 96, 384 and 1536-well formats
from diå erent manufacturers. Pharmacopeia’ s internal
research combined with multiple collaborative and cus-
tomer oriented screening eå orts against the 6,000,000‡
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reformatting between diå erent plates. In response to this
challenge, Pharmacopeia’ s HTS and Research Engin-
eering groups have developed a complete family of
reformatting tools. This presentation will describe some
of the internally implemented equipment and techniques.
Among the presented instrumentation will be the indus-
try’ s fastest universal Single Channel Reformatter (pa-
tent pending), the Manual 96Ð 1536 Reformatter, and a
fully automated reformatting system capable of handling
all types of plates, as well as related liquid dispensing,
washing, ® lling and other tasks.
Automation and organization for the combinator-
ial chemistry/medicinal chemistry interface
Bob Kennedy, Parke-Davis Pharmaceutical Research, Ann Arbor,
MI
As libraries of compounds have become commoditized,
Combinatorial Chemistry groups in large pharma have
shifted their focus from library generation to lead opti-
mization. Here, the marginal returns on application of
combinatorial techniques to medicinal chemistry projects
can be quite high. However, success is often determined
by the ability to shift focus from synthetic route develop-
ment, production techniques, diversity and large
numbers of compounds to an emphasis on accessibility
of automation, puri® cation and turnaround time of
project arrays. This talk will focus on both the technology
and organizational structures that leverage medicinal
chemists.
Approaches towards integrated high throughput
synthesis, analysis and puri￿ cation
Shahzad Rahman, Discovery Chemistry Europe, SmithKline
Beecham Pharmaceuticals, Harlow, Essex, UK
Traditionally chemists working in the pharmaceutical
industry have synthesized a single compound at a time
for biological testing. This approach is by its very nature
extremely slow and costly. The need to accelerate the
drug discovery process has led to the creation of high
throughput methods that allow the synthesis of large
numbers of compounds either as mixtures or by parallel
synthesis of single compounds. Routinely, robotic chemi-
cal synthesizers are used for manipulation and synthesis
of multiple compounds. Using these techniques hundreds
to thousands of compounds can be synthesized and
subsequently analyyed and puri® ed in the time taken to
prepare just a few analogues by orthodox methodology.
The presentation will describe strategies at SmithKline
Beecham for high throughput compound production and
processing. In one approach, compounds are synthesized
in a semi-automated mode using the IRORI directed
sorting methodology. In a second approach, each com-
ponent of the high throughput process has been auto-
mated using specialized robots. Large-scale synthesis, of
proprietary diversity reagents, is achieved using the
Zymark solution phase synthesizer. Synthesizers (e.g.
Myriad, Bohdan RAM, etc.), capable of carrying out
complex and demanding chemistry, are used for high
throughput library production. Equipment for rapid
down stream processing (e.g. l/l extraction), sampling,
puri® cation and analysis have also been automated. The
systems used at each stage of the process will be discussed
using examples to demontrate their capabilities. The
presentation will also highlight key issues and challenges
in combinatorial technology such as hardware control,
data handling and other bottlenecks.
Fast synthesis at the Janssen Research Foundation
Davy Petit, Marc Schroven, Janssen Research Foundation,
Belgium
This presentation gives an overview of how parallel
synthesis is performed in the Fast Synthesis Lab, a
subunit of the combichem group at the department of
medicinal chemistry. The entire work¯ ow and data¯ ow
are automated. A Zymark robot is used for lab-intensive
manipulations. An automated preparative LC/MS pur-
i® cation system delivers compounds with a minimum
purity of 90% at an average yield of 50mg. A high
throughput analysis tool determines the purity of the
compounds based on MS and UV data. Data handling
(calculations, registration) is accomplished using MS
Excel, Accord Combichem and Accord for Excel.
Increasing throughput of LC–MS–MS bioanalysis:
shortening chromatography versus multiplexing
Mohammed Jemal, Bioanalytical Research, Metabolism and
Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Re-
search Institute, New Brunswick, NJ
With the recent advances made in sample preparation for
analysis of biological samples by LC-MS-MS, the sample
extraction time has been reduced to less than 30 seconds
per sample. Consequently, a chromatographic run time
of even two min now appears to be comparatively long.
Therefore, there is a renewed impetus to either shorten
the chromatographic time or to otherwise achieve analy-
sis of multiple samples within the same chromatographic
time through some sort of multiplexing. This presentation
will deal with the pros and cons of the diå erent
approaches to increasing sample throughput by LC-
MS-MS bioanalysis.
An automated system for rapid determination of
semi-optimized MS/MS conditions for bioanalyti-
cal mass spectrometry
Kevin Whalen, Katrina Rogers, Mark Cole and John Janis-
zewski, Candidate Enhancement P¢zer Central Research, Groton,
CT
The process of high-throughput ADME screening can
generate thousands of samples for analysis in a very short
timeframe. Before quantitative LC/MS analysis can be
applied to the new chemical entities (NCE) entering
these screens, valid MS ion-monitoring conditions must
be determined for each compound. We have developed
an automated system for the rapid unattended determi-
nation of semi-optimized MS and MS/MS conditions
(e.g. precursor ion, product ion, polarity, and collision
energy) for new chemical entities. The system features a
custom software application that coordinates user de® ned
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energies to be scanned, along with control of the associ-
ated sample introduction hardware. The system uses two
¯ ow injections of each analyte to determine the semi-
optimized MS and MS/MS conditions. The ® rst injection
is used to determine optimal polarity and a precursor ion
using a rapid Q1 scanning protocol. The Q1 scan is
reviewed automatically and the logical precursor ion is
chosen relative to expected mass ion ([M¡H]¡ and
[M+ H]‡). The precursor ions are then used to pro-
grammatically build injection sequences for product ion
scanning. A color-coded graphical interface is used to
facilitate data review. Any unexpected precursor ions
obtained during Q1 scanning, and/or suspect ion transi-
tions are ¯ agged and corrected at this time. The data
review component of the system has selection criteria
built in that can recognize common adducts or losses and
¯ ag transitions below a pre-de® ned intensity threshold.
Complete MS and MS/MS conditions are obtained for
96 compounds within 60 minutes and the resulting data
are available as injection sequences for direct import into
the Sciex sample control function for a quantative LC/
MS run.
Integrating automation and LC/MS for drug dis-
covery bioanalysis
David T. Rossi, Bioanalytical Core Group, Department of
Pharmacokinetics, Dynamics and Metabolism, P¢zer Research,
Ann Arbor, MI
A novel, integrated approach for automated sample
handling in drug discovery bioanalysis is described. The
process includes aspects of animal study design, biological
sample collection, sample processing and high through-
put API LC/MS operating in under multiple reaction
monitoring (MRM). A semi-automated 96-well liquid-
liquid extraction technique for biological-¯ uid sample-
preparation was developed and used in conjunction with
the integrated sample handling approach. One plate of
samples could be prepared within 1.5 hr compared to 4
hours for a manual approach, and the resulting 96-well
plate of extracts was directly compatible with the LC/
MS. Feasibility studies for development of the process
included sample collection map generation and infor-
mation management, sample collection formatting,
evaluation of alternative dilution schemes for high con-
centration samples, choice of biological ¯ uid, and evalu-
ating the capabilities of the two liquid-handling
workstations. Numerous comparisons between the new
approach and conventional sample handling approaches
gave equivalent drug-quantitation results for several
example compounds. This new sampling process has
approximately doubled the eæ ciency (as measured by
studies assayed per month) of drug discovery bioanalysis
in our laboratory. The approach was also used in
conjunction with time-of-¯ ight mass spectrometry instru-
mentation (LC/TOF/MS) to quantify and characterize
the disposition of simultaneously dosed example drug
compounds in rats. Likely strategies for future automated
sample preparation workstations are described.
Integration of new technology for increasing
throughput in new drug discovery using HPLC-
API-MS/MS: strategies and issues
Walter A. Korfmacher, Department of Drug Metabolism and
Pharmacokinetics, Schering-Plough Research Institute, Kenil-
worth, NJ
HPLC combined with atmospheric pressure ionization
(API) tandem mass spectrometry (MS/MS) has become
a very useful tool in the pharmaceutical industry. The
technique of HPLC-API/MS/MS has become very im-
portant for both drug discovery and drug development
programs. Because of combinatorial chemistry as well as
the demand for higher throughput of drugs in the
discovery stage, there is a need for techniques that can
be used to increase sample throughput in the analysis of
samples from pharmacokinetic (PK) studies of new
compounds; i.e. what is needed is high-throughput
pharmacokinetics, HTPkS. One of the bottlenecks to
HTPkS is the PK sample assay step. Strategies for
increasing throughput will be described. Bottlenecks that
are preventing higher throughput will also be discussed.
Quali￿ cation of a Zymark MultiDose automated
dissolution workstation for dissolution testing of
fexofenadine HCL capsules
Tom A. Steinman, Aventis Pharmaceuticals, Inc., Kansas City,
MO
A manual, multi-point dissolution test for powder ® lled
capsules was transferred to an automated dissolution
method utilizing the above systems. Both methods re-
quire an HPLC ® nal analysis.
Several MultiDose system parameters were evaluated to
ensure product result integrity and equivalency. These
included carryover studies, line ¯ ush studies, vessel wash
studies, ® lter studies, and sample evaporation studies.
The most critical evaluation was the statistical analyses
(equivalence) of the product results from both methods.
Automation in pharmaceutical analysis-￿ ber optic
dissolution
Abe Kassis, Kevin C. Bynum, Lane Gehrlein, Philip Palermo,
Purdue Pharma L. P., Ardsley, NY
A novel UV in-situ detection testing methodology has
been developed for the analysis of dissolution pro® les, for
solid pharmaceutical dosage forms. The system utilizes 12
dip type UV probes to monitor the amount of active
component releases during a dissolution test. Each probe
is placed inside a dissolution vessel and remains in the
vessel for the duration of the test. Each probe is then
coupled to a spectrometer by means of a ® ber-optic light
guide. A total of twelve PDA spectrometers are utilized to
collect an absorbance spectra from each probe, at set
time intervals, during the dissolution test. After setup, the
system runs without analyst intervention for up to 72
hours. All calculations and results are automatically
calculated, and secured in real time. This publication
presents data from a number of pharmaceutical dosage
forms, generated in a production environment. The
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also be presented.
Expediting the formulation development process
with the aid of automated dissolution in analytical
research and development
Jon P. Sadowitz, Barr Laboratories, Pomona, NY
The development of drugs in the generic pharmaceutical
industry is a highly competitive arena of companies vying
for few products that are coming oå patent. Companies
that have been successful in this arena are those that have
met or surpassed the critical timeline associated with trial
formulation development, analytical method develop-
ment and submission batch manufacturing and testing.
Barr Laboratories has been successful in the generic
pharmaceutical industry for several reasons, one of which
includes automation. The analytical research and devel-
opment department at Barr employs the use of auto-
mated dissolution early in the lifecycle of a potential
product. This approach dramatically reduces the ` Time
To Market’ on average for a number of products. The
key to this approach is the network infrastructure of the
formulation and analytical research and development
departments. At Barr Laboratories Inc., our cooperative
ability to work and communicate together has driven the
departments to streamline and matrix their work eå orts
and optimize resources and time.
The discussion will overview how Barr Laboratories Inc.
has been successful with automation and give a case study
of products that have moved with rapid pace through the
development cycle.
Evaluation of an automated Vankel type VII appa-
ratus for testing of extended release OROS
1
tablets
Kalpana Chaturvedi and Karen Chang, ALZA Corporation,
Mountain View, CA
An automated Vankel USP type VII dissolution appa-
ratus has been evaluated for testing of extended release
OROS
1 tablets. Reproducibility as well as sample sol-
ution evaporation rate, homogeneity, and carryover were
studied using ALZA OROS
1 tablets. Performance of
this automated tester was also compared to the ALZA
USP VII bath that requires several manual sample
preparation steps. The OROS
1 tablets were released
for 10 hours at 378C, and the released sample solutions
were collected via a Vankel 8000 collector. Sample
solutions were then analyzed using a validated isocratic
HPLC method. Homogeneity of the sample solution was
evaluated by manually removing the sample solution
from the top, middle, and bottom of the same sample
tube. Reproducibility was evaluated by measuring the
release rate of six tablets per day on 3 separate days. The
data showed that both ALZA and Vankel VII apparatus
exhibited similar release-rate pro® les for the OROS
1
tablets studied. An evaporation study showed very mini-
mal evaporation during the 10-hour release interval. The
sample solution was found to be homogenous, thus
allowing automated transfer from the sample tube to
the VK 8000 collector. Carryover from one interval to
the next was insigni® cant (1%) and similar for both
ALZA and Vankel release-rate testers. Release-rate
pro® les from all three reproducibility sets were very
comparable. It is concluded that the Vankel VII bath
with automated collector can be employed for release-
rate testing of ALZA OROS
1tablets.
BioPrintTM: the leading edge in drug pro￿ ling—
optimizing the hit to lead strategy
Michael Entzeroth, CEREP, Rueil-Malmaison Cedex, France
Modern drug discovery produces an increasing number
of lead and development compounds with a vast number
of related results, triggered by the installation of modern
technologies, such as combinatorial chemistry and (ultra)
high throughput screening ((u)HTS). Lead selection, to
initiate successful discovery and development programs,
has become more diæ cult and sometimes a matter of
serendipity. As a consequence, the pharmaceutical in-
dustry has put emphasis on the development and auto-
mation of secondary tests. High throughput pro® ling
using robotics and automated workstations allows us to
accumulate a broader knowledge on the hits identi® ed in
the primary screening. These data give rise to a more in-
depth analysis of the compound pro® les with respect to
their pharmacological and pharmaceutical properties.
The avaluation of these pro® les provides knowledge-
based decision criteria by distinguishing selective from
promiscuous candidates and clustering candidates and
even targets in hierarchical families. BioPrintTM is a data
mining approach which generates those models that
correlate molecular features of a compound to patterns
of in vitro biological activity and patterns of in vitro
activity with in vivo biological activity. This data mining
opens a new approach for candidate selection and early
discovery activities, such as target identi® cation or
library design and will result in the long term cost savings
due to reduced failure rates and time spent on the
research and development process.
Enhancing drug discovery: utilization of VITATM
￿ uorescently labelled ligands in high throughput
capillary electrophoresis screening
Yuriy Dunayevskiy1, Tom Riera2, Paul Gallant2, Dallas
Hughes1 and John Finn2, 1Cetek Corporation, 2Cubist Pharma-
ceuticals, Inc
The rise in bacterial resistance has lead to an increased
emphasis on target-based methods for antibacterial
discovery. An HTS assay is a key component in most
target-based strategies. For many targets, however,
development of a HTS assay is diæ cult and requires
considerable time prior to initiation of screening. The
VITA (Validation In vivo of Targets and Assays) process
validates bacterial targets and generates a peptide ligand
that is used in ¯ uorescent polarization (FP) HTS assays.
This talk will illustrate the use of a novel capillary
electrophoresis (CE) screening technology applied to a
VITA validated target and peptide. A ¯ uorescent CE-
HTS binding assay was developed and optimized in less
than 1 week. The CE assay required signi® cantly less
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allowing the screening of mixtures. Details about the CE-
HTS assay performance will be presented.
Automated high throughput capillary electrophor-
esis (HT-CE) screening
Dallas E. Hughes, Herbert J. Hedberg, James N. Little and
James L. Waters, Cetek Corporation, Marlborough, MA
A new screening technology, based on capillary electro-
phoresis, is being widely accepted as an alternative to
conventional screening assays. HT-CE identi® es target-
binding ligands in synthetic compound and natural
extract libraries. The assay can rapidly rank ` hits’ by
binding aæ nities and can distinguish between diå erent
target binding sites. Assay development is easy and fast
with no requirements for competitive ligands, radioactive
reagents, antibodies, or knowledge of the target’ s bio-
logical function.
Since no high throughput CE instrumentation was
available, this talk will describe new automated instru-
mentation and capabilities for performing HTS by CE.
Examples of various assays and assay formats will be
described using this new instrumentation.
The Luminex LabMAPTM system: a rapid, homo-
geneous multiplexed assay platform
Lekha Patel, Kerry Oliver*, Janet Davis, Brian Magliaro, Lee
Peligrino, Scott Wadsworth, John Siekierka, Alex Collins,
Robert Zivin. The R.W. Johnson Pharmaceutical Research
Institute, Raritan, NJ, *Luminex Corporation, Austin,TX
The Luminex device combines fast, microsphere-based
assays with the ability to carry out parallel reactions in
single wells The LabMAP system is a multiplexing tech-
nology capable of rapidly analyzing up to 100 diå erent
analytes/reaction products in a single sample. Assays are
developed in a homogeneous format on unique sets of
` ¯ uorescently bar-coded’ microspheres and quanti® ed by
the ¯ uorescence intensity of a reporter ligand. Most
assays formatted for microtiter-based assays are amen-
able to miniaturization and rapid transfer to the bench-
top LabMAP system. These include: immunoassays,
enzymatic assays, transcriptional pro® ling, and receptor
binding assays. Of particular note are the Insulin-
induced receptor phosphorylation (a whole cell system)
and the ` multiplexed’ cytokine assays. Assay details and
results will be presented.
Xpress-ScreenTM mRNA detection direct quantita-
tion of speci￿ c mRNA in cell lysates in an auto-
mated, high-throughput format
Kimberly Spo¡ord, Applied BiosystemsöTropix Division,
Bedford, MA
Monitoring changes in gene expression levels is the most
informative and rapid approach to date for evaluating
the eå ects of potential drugs on the cell. An ideal HTS
format of that approach should provide reliable informa-
tion output in a cost-eå ective manner. Current methods
such as a reporter gene approach, quantitative RT-PCR,
and other mNRA detection assays do not adequately
ful® ll these criteria. A novel assay for precise and direct
quantitation of speci® c mRNA in cell lysates is presented.
This method is based on the detection of multiple-
biotinylated long single-stranded DNA probe/mRNA
hybrids captured on a streptavidin-coated microplate.
Detection of the hybrid by a speci® c alkaline phos-
phatase-conjugated antibody features several levels of
signal ampli® cation. The assay is adapted for use on
the AllegroTM UHTS system (Zymark Corporation,
Hopkinton, MA). This method allows for rapid assay
development in any cell type including yeast, multiple-
gene readout in 384-well plates, and detection of 1-2
copies of mRNA per cell. In contrast to reporter gene
systems the method re¯ ects not only native regulation of
synthesis but also the rate of degradation of the mRNA in
response to the signal. Diå erent applications in monitor-
ing the cellular regulatory network using this method are
developed.
Screening in the 21st century: quality data with
UHTS speed
Carol Ann Homon, Mohammed A. Kashem, and Richard M.
Nelson, Boehringer Ingelheim Pharmaceuticals, Inc., Ridge¢eld,
CT
In the early days of high throughput screening, the
quality of data produced was often compromised by
inherent limitations in available automated devices and
assay biochemistry. What worked well in manual assays
on the bench did not perform at the same level in the
unforgiving environment of the automated screen. Ad-
vances in technology have completely reversed this
situation. State-of-the-art liquid handling, robotics, and
detection technology, together with new HTS-enabling
assay biochemistry, have elevated the data quality of
ultra-high throughput screens above that which can be
achieved using manual assays and older methods. The
major force that has propelled this quiet revolution in
screen quality is the advent of assay biochemistries
designed speci® cally for HTS and UHTS. Clear leaders
in this arena are FRET, TR-FRET, and FP hom-
ogeneous, or mix-and-read, formats, whose spectacular
performance in ultra-high throughput screening is un-
rivalled by radiometric, immuno¯ uorescent, or immu-
noenzymatic methods. This talk will review our
experience with DELFIA, LANCE, FP, and radiometric
UHTS run on the Zymark Allegro robotic system,
prosecuting several diå erent molecular targets. We will
describe certain ¯ uorescent screens that have produced
Z0 values as high as 0.9 and Z values of 0.7 across run sets
of several hundred plates.
Workstations versus fully automated systems:
pick your poison
Rich Harrison, DuPont Pharmaceuticals, Wilmington, DE
A topic that has been raised at many an automation
meeting and bar room debate is the resolution of the age
old question: it is better to equip a high throughput
screening lab with several small, dedicated workstations,
or to run with a fully integrated automation system?
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the ability to perform laborious, complex procedures
without manual intervention. Fully automated systems,
while able to process large numbers of samples in less
time, have been plagued by down time. Simply put, the
more things to break the more things will break. While
the arguments are passionate for both sides, the choices
are most often made by economic, rather than practical
and scienti® c criteria. This talk will focus on these often
overlooked practical and scienti® c criteria. Examples of
real world assays performed on both workstations and
fully automated systems will be compared in terms of ease
of use, reliability, and performance.
High-throughput assay and analysis strategies for
pre-clinical ADME/Tox screening
Je¡ Whitney, Novatia Corporation, Yardley, PA
In recent years much progress has been made in the drug
discovery areas of the pharmaceutical industry towards
automating the synthesis and functional screening of
small molecules. Hundreds of thousands of compounds
can be synthesized and screened using combinatorial
chemistry and high-throughput functional screens in a
fraction of the time previously required. However, as
many discovery scientists are now realizing, quantity
alone does not ® ll the drug development pipeline with
compounds more likely to reach the marketplace: an
increasing emphasis on quality is emerging. This greater
emphasis on quality requires smarter decisions for library
design and lead candidate selection by incorporating
ADME/Tox tendencies that shed light on a compounds
potential ` drugability’ . Two major approaches are evolv-
ing for obtaining pre-clinical ADME/Tox information:
in-silico computer algorithms which attempt to make
predictions based mainly on molecular structure, and
in-vitro assays which monitor potentially relevant bio-
chemical transformations and interactions. This talk will
focus on assay design and detection strategies for in-vitro
screens used to physically measure ADME/Tox par-
ameters such as metabolic stability, permeability, solu-
bility, inhibition, etc. The use and bene® ts of high-
throughput LC/MS as a direct structural detector for
these assays will be highlighted. Emphasis will also be
placed on issues of sample preparation, automation and
throughput.
ADMET pro￿ ling of combinatorial libraries and
lead optimization for drug discovery
E. Priya Eddy, Millennium Pharmaceuticals, Cambridge, MA
Estabishment and validation of high throughput ADME/
TOX assays is extremely important for 1) future library
design; 2) validation of the medicinal relevance of the
libraries and 3) lead optimization and selection of drug
discovery candidates.
A battery of ADME/TOX assays consist of: Aqueous
solubility, Metabolic stability, CYP-450 Inhibition, In-
testinal permeability, Cytotoxicity and cell proliferation
assays and Protein Binding measurements. About 4000
library compounds (10% of libraries) passed through
each of these assays (except protein binding under
validation) that have been automated both for liquid
handling and data processing. Details will be discussed.
Aqueaous solubility at 10uM and 100uM was evaluated
in a 96-well plate by using a UV spectral scan from 190±
300nm. Metabolic stability of compounds at 10uM in
human liver microsomes ‡S9 in the absence and presence
of NADP was evaluated using modi® ed Gentest methods.
Fluorescence based CYP-450 Inhibition assays at 10uM
compound concentrations were evaluated which include
4 major P450’ s: lA2, 2C9, 2D6 and 3A4 (modi® ed
Gentest methods). Interstinal permeability assays were
run using Caco-2 cell cultures (18± 25 days) in a 24-well
plate format. Compound permeability (100uM) was
evaluated in the basolateral-to-apical direction. Cyto-
toxicity and cell proliferation assays were run using
sub-con¯ uent MDCK cell cultures and incubation of
library compounds (100uM) for 24h. Cellular viability
and proliferation were determined by using XTT reagent
(Roche).
Results: Throughput for each of the assays was between
800± 120 compounds/week/person except for permeability
assays (300 compounds/week). A database containing
such ADME/TOX properties for compound libraries will
be crucial in SAR for future library design.
Plasma pooling and continuous blood withdrawal
methods to increase throughput for In Vivo phar-
macokinetic screening
Cornelis E.C.A. Hop, Qing Chen, C. Keohane, Zhen Wang and
Cloria Kwei, Merck Research Laboratories, Rahway, NJ
Due to the amount of combinatorial chemistry and other
parallel synthetic approaches, the number of compounds
that have to be screened pharmacokinetically in vivo has
increased dramatically. Automation of several steps dur-
ing the extraction and analysis has been employed to
increase throughput. Alternatively, mixtures of several
compounds can be dosed to animals followed by analysis
of the samples by LC-MS/MS. Using this approach
introduces the possibility of drug-drug interactions. To
circumvent these disadvantages individual compounds
can be dosed, followed by pooling of plasma samples of
animals dosed with diå erent compounds. As an alter-
native we investigated a method in which appropriate
aliquots of the plasma samples obtained from all time-
points are pooled, yielding one sample that has a
concentration proportional to the pharmacokinetic
area-under-the-curve (AUC). Using this procedure there
is only one sample per animal instead of 8± 10 samples.
Because the animal receives only one compound, phar-
macodynamic information can still be obtained and
drug-drug interaction is not a concern. Of course this
approach can also be combined with cassette dosing. In
the latter case, one sample will provide the AUC for all
compounds. This pooling method represents a fast
screening tool in the discovery phase of drug develop-
ment and is probably most useful when plasma AUC
values after oral and/or intravenous dosing are the main
concern of the discovery program. Nevertheless, this
pooling method still necessitates a considerable amount
of pipetting. Therefore, we investigated continuous blood
withdrawal to obtain one sample for each animal.
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13A clinical trial on a plate: the potential of 384
format SPE for high throughput bioanalysis using
LC-MS-MS
Robert Biddlecombe and Steve Pleasance, Glaxo Wellcome, Park
Road, Ware, UK
The bene® ts of moving to higher density plates (e.g. 384)
have already been established in HTS applications, e.g.
less reagents, faster screening, smaller sample volume. In
this work we evaluate the potential of higher format SPE
for bioanalysis using LC-MS/MS.
Project compounds with existing, validated SPE-LC-MS/
MS methods in the 96 well format were selected for the
work in order to identify the advantages in moving to a
higher, denser format. As there are no commercially
available 384 well format SPE blocks, several prototype
microtitre plates were manufactured for this work.
All liquid handling was automated using a Packard
MultiPROBE II robotic sample processor and a 96/384
Rapid plate. Solvents for conditioning, washing and
eluting were drawn through the SPE block using cen-
trifugation. The SPE extracts were analysed by LC-MS/
MS using HP1100 pump, a CTC LC PAL auto-sampler
and a PE-Sciex triple quadrupole mass spectrometer
using a TurboIonspray interface and selected reaction
monitoring.
The Pros and Cons of 384 SPE will be discussed. These
include:
. reduced sample volume;
. validation;
. the potential for cross well contamination;
. the ratio of calibration standards to unknown
samples;
. time required for sample preparation and overall
analysis time (384 versus 4£96);
. costs of consumables and re-tooling for peripherals;
. extract stability.
Managing the challenge of e‡ cient sample distri-
bution in an international company with di´ erent
research sites
Gerhard Mihm, Lead Discovery, Screening Support Team,
Boehringer Ingelheim Pharma KG, Biberach, Germany
In the last few years the increasing throughput in HTS
and CC has put an enormous pressure on the sample
management labs (dispensaries) to make all samples
available to the HTS groups, the biological homelabs
and analytical groups in an enormous format and on
time. In addition, eæ cient exchange of the necessary
sample data is essential for rapid testing and reporting
of the results. This situation is particularly diæ cult in
companies with many research sites and hence diå erent
destination of shipments.
BI is a worldwide operating pharmaceutical company
with research sites in Europe and America. Compound
collections are maintained in Germany and the US, while
biology is done at all research sites. Samples are distrib-
uted from the compound stores to the sites on a regular
basis.
We have developed a strategy enabling an eæ cient
worldwide sample exchange based on the shipment
mainly of solutions. In the BI dispensary in Biberach
several workstations for the solubilisation of the samples
and aliquotting the solutions into plates and tubes for
individual sample access are available. In addition, the
vast number of tubes are handled with an automated
sample storage and retrieval system that has been im-
plemented together with REMP.
The exchange of the associated data is done via direct
database links and a worldwide data turntable based on
ORACLE technology. Details about our strategy and the
automation established will be presented.
A survey of the various plate sealing technologies
Michael Routburg and Carol Ann Homon, Boehringer Pharma-
ceuticals, Inc., Ridge¢eld, CT
High throughput screening is dependent upon the qual-
ity of its samples stored as DMSO solutions. The storage
and shipment of liquid libraries in plate format requires a
proper sealing method which will ` contain’ the solution
within its well (isolated from the neighboring com-
pounds) upon thawing. The seal must not introduce
any impurities into the solution either by direct contact
of the DMSO with the seal or by indirect contact
(volatile components).
The results of an evaluation survey of the various sealing
methods (cap mat, adhesive, heat and gasket) and the
present commercial devices will be presented and com-
pared. Advantages and disadvantages of each will be
highlighted. Automation options associated with the
various methods will also be discussed.
Optimizing production of serially diluted com-
pounds and distribution to multiple targets
Cole O. Harris and Stephanie L. Schweiker, GlaxoWellcome,
Inc., Research Triangle Park, NC
The need for a multiple-target compound selectivity
program led to the establishment of a single robotic
system that produces a compound’ s serial dilution and
its distribution to multiple replicate assay plates. A Tecan
integrated into a Zymark robotic system produced the
serial dilutions and the subsequent replicate assay plates
were produced quickly and accurately by an eæ cient use
of the carousels and rapid plate. Currently this process
allows for the production of over 200 serial dilution assay
plates in a workday.
Implementation of an automated data transport
architecture for discovery analytical instruments
over a secure corporate intranet
Martin M. Echols, Bristol-Myers Squibb, Lawrenceville, NJ
The dramatic increase in industry utilization of combi-
natorial chemistry technologies and the explosion in
automation for high throughput screening have had a
tremendous enabling eå ect on the pharmaceutical drug
discovery process. But these advantages have also
brought with them new challenges and foremost of these
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paper addresses a crucial part of this new challenge, the
fast, reliable and automated transportation of analytical
data from its source in laboratory to its destination, the
LIMS or other point of access. An architecture is
presented that utilizes intranet network elements com-
monly available today within most business both small
and large. An implementation of this architecture in
Microsoft Windows NT using the popular development
tool Visual Basic and commercial software components is
described with an evaluation of its performance.
Computational chemistry, data mining, high-
throughput synthesis and screening: informatics
and integration in drug discovery
Charles J. Manly, Neurogen Corporation, Branford, CT
Drug Discovery today includes considerable focus of lab
automation and other resources on both Combinatorial
Chemistry and High-Throughput Screening. Computa-
tional Chemistry has been a part of pharmaceutical
research for many years. The real bene® t of these tech-
nologies is beyond the exploitation of each individually.
Only recently have signi® cant eå orts focused on eå ec-
tively integrating these and other discovery disciplines to
realize their larger potential. This presentation will
describe one example of these integration eå orts. Ex-
amples from experiences at Neurogen from the last 6
years will be described.
Improved e´ ectiveness in mixture screening
through better data management
Linda Traphagen, Abbott Laboratories, Abbott Park, IL
Screening using compound mixtures rather than indi-
vidual compounds can save signi® cant time, and con-
siderably reduce costs. However, identi® cation of active
hits in mixtures can be diæ cult, and can yield ambiguous
information. Abbott’ s internally developed screening
database allows complete tracking of all the compounds
in these screening wells, along with their associated data,
thereby facilitating precise identi® cation of all active
compounds while maximizing the cost savings associated
with screening in mixtures.
At Abbott we screen mixtures of ten compounds, which
originate from an orthogonal mixing of 100 source plates
to yield 20 mixed screening plates in 96 well format. Each
compound is represented twice in unique mixtures. Hits
are designated as one of two types: 1) matched ` hits’ and
2) unmatched ` hits’ . Matched hits are those where the
compound has shown activity in both its respective wells.
Unmatched hits show activity in only a single well. In the
latter case, there is no corresponding active well to
indicate which of the ten possible compounds in the
active well is responsible for the well’ s activity.
Con® rmation of activity is done as single compound tests.
Retests are performed on all reported matched com-
pounds and on the ten compounds from any unmatched
wells. When a matched compound fails to con® rm in
retests, the two wells of the original matched hit are
demoted to unmatched status. This process thus identi® es
an additional eighteen compounds making them avail-
able for retests. This re-iterative testing process enables us
to identify all active compounds in a mixed compound
screening format.
Chemometrics in high throughput systems—
utilization issues and strategies in using multi-
variate data analysis in integrated robotioc
systems and Lab-on-Chip analyses
Richard P. Gill, Veritec, Inc., Essex, CT
High Throughput Screening (HTS) incorporating mul-
tiple tests and instrumentation within the same system
generates reams of multivariate data that can be diæ cult
not only to process but more importantly to interpret.
Utilization of chemometrics in the analysis of multi-
variate HTS data sets can provide substantial analysis
bene® ts.
Chemometrics is a broad ® eld that can be de® ned as the
application of mathematical and statistical techniques to
chemical data. This discipline uses mathematical and
statistical methods to: (1) extract out the maximum
amount of information from large multivariate ` chemical’
data sets, and (2) design or select optimal measurement
procedures and experimental methods.
The presentation provides a nonmathematical overview
of the challenges in building and operating HTS systems
incorporating multivariate data analysis. Actual data
examples, issues, and strategies stemming from the use
of this approach in HTS and Lab-on-chip systems will be
discussed.
Managing laboratory automation in a contract
laboratory
Darren Jantzi, Stability Manager, PPD Development, Mid-
dleton, WI
Automation provides contract research organizations
(CROs) a medium to provide high volume, compliant
analysis to clients. Evaluating and selecting automation
that is worthwhile transferring to a contract site is an
important process in a successful program.
Stability testing for ® nished pharmaceutical products
lends itself to automation in a contract environment.
There is a large volume of repetitive work extending up
to 5 years. If automation is managed properly it can
accelerate bringing a drug to market through more
consistent and timely analysis of stability data.
Automation also brings with it a host of challenges: cost,
technology transfer, maintenance and calibration, IQ/
OQ/PQ, data organization, and more. However, the
bene® ts derived from automation, including increased
eæ ciency, quality, and productivity outweigh these
potential challenges.
This talk will focus on a contract lab’ s experience with
implementing and managing automation through case
studies.
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from a customer perspective
Nigel North, SmithKline Beecham Pharmaceuticals, Harlow,
Essex, UK
Automation requires signi® cant capital investment and
for contract laboratories this funding may be diæ cult to
justify. However, with increasing commitment to the
automation of dosage form analysis by pharmaceutical
companies and the adoption of automation earlier in the
development process, outsourcing of automated methods
will be an important requirement in the future. Contract
laboratories that do not have automation equipment will
not be able to compete eå ectively for business as those
that have this capability. The bene® ts to the customer of
outsourcing automated methods will be discussed to-
gether with the potential problems for the contract
laboratory in forming a strategy to meet this need. The
adoption of new technology in other development func-
tions (eg. bioanalysis) by pharmaceutical companies and
contract facilities has been very successful. The learnings
from this situation will also be brie¯ y outlined to provide
some perspective around the implementation of auto-
mated methods.
An automated approach to the supply of samples
for screening
Terry Wood, Medicinal Technologies, P¢zer Ltd., UK
Some years ago the Drug Discovery teams at P® zer Ltd.
In the U.K., predicted that sample supply would become
a rate-limiting factor in successful implementation of high
throughput screening programs. A team of scientists was
assembled to develop the concept and speci® cation of an
automated system that would securely store our rapidly
growing sample bank, and supply test plates to an
intensive program of primary and follow-up HTS.
Following competitive tender, a Manchester based com-
pany, RTS Thurnall Ltd., was selected to design and
build an Automated Liquid Sample Bank (ALSB) at
P® zer’ s U.K. base in Sandwich, Kent. An intensive
program of joint meetings, acceptance testing and inte-
gration with P® zer’ s existing systems culminated in the
launch of the ALSB on April 12th 2000, fully automating
the process of liquid sample ordering and delivery.
The system contains DMSO solubilized samples stored at
¡208C in microtitre formatted racks of tubes, and is
capable of assembling collections of up to 6000 individu-
ally selected tubes or 500 racks of tubes in a 24 hour
period. This period includes time to thaw the samples,
aspirate them and dilute them to the concentration
requested. The scientist placing the order does so from
his/her desktop PC, specifying the compounds to be
screened and details of concentration and dilutent re-
quired. From commitment of this order, the process is
entirely automated until the ALSB operators unload the
completed test plates for delivery.
The key hardware components of the system are a freezer
store with a capacity of 2.5 million samples, a defrost
station, and twin liquid handling cells all connected by a
transport system of infeed and outfeed conveyors. The
whole system is controlled by an order processor, which
directs all decisions on the most eæ cient use of hardware,
appropriate dilution algorithms and also controls the
various administration functions available. Orders are
created using updated versions of sample ordering and
experiment creation software already in place at Sand-
wich, with which our scientists are familiar. A vital
requirement, prior to ® nal acceptance, was the successful
integration of these software packages with the ALSB
database. We are now able to support primary HTS,
follow up active compounds, and deliver samples to IC50
programs at a rate in excess of our current requirements.
In addition, we can assemble bespoke selections of
compounds in numbers that would have been previously
impractical. Adjacent support hardware allows purity
checking of stored samples, and reformatting of ALSB
output, if required, by the screening robotics.
Following a successful partnership with the system
suppliers, RTS Thurnall, the P® zer ALSB facility is up
and delivering. The system forms a vital central com-
ponent of lead discovery and optimisation operations at
Sandwich.
Automated liquid handling in compound dissolu-
tion and distribution robots
Kevin Olsen, Wyeth Ayerst Research, Pearl River, NY
The preparation of highly concentrated DMSO/Com-
pound liquors is the starting point for most drug dis-
covery screening. Because of the physio-chemical
properties of the liquors, the frequent presence of un-
dissolved materials, and their importance to the discovery
organization, specialized robotics are often required for
this task. This presentation follows the development and
optimization of automated pipetting devices used in the
Research Compound Bank by the Robotics & Automa-
tion Department.
SmartPlate cassette simpli￿ es compound hand-
ling
Je¡rey A. Karg, Boston Innovation, Inc., Cambridge, MA
The twin revolutions of geonomics and combinatorial
chemistry have created an explosion in the number of
compounds for screening. Managing these large com-
pound libraries eæ ciently is a big challenge. A consor-
tium of industry leaders is guiding development of the
SmartPlate Cassette, which integrates shipping, storage
and sub-microliter non-contact dispensing of compounds.
This approach could be the basis of a new industry
standard for compound management. The presenter will
highlight implementation examples and current perform-
ance data.
The many faces of the Hamilton Microlab 2200
liquid handler station at Bristol-Myers Squibb
Joseph Yacobucci, Benjamin Carvalho, Edward Pineda,
Jonathan Severino, James Mongillo, Steven Innaimo, Richard
Belval, Bristol-Myers Squibb, Wallingford, CT
This presentation will describe the many implementa-
tions of the Hamilton Microlab 2200 in Lead Discovery
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include single, 8, 16, and 48 channel devices, software
and hardware, operations into 96, 384, and 1536 well
microplates, and use of liquid sensing to replenish
reagents on the deck as needed. As a high-speed liquid
handler, it was inexpensive, easy to operate, and very
¯ exible, thus making it very useful for original thought.
Hardware and software can easily be customized for
highly successful use, as a workstation, or in a high-speed
fully automated robotic system. Also to be presented are
the possible future predictions of new faces for the
Hamilton Microlab 2200.
A unique robotics solution to achieve routine 1536-
well cell-based screening
Daniel Sipes, Novartis Institute for Functional Genomics, San
Diego, CA
Assay miniaturization can reduce screening cost/well
while increasing throughput. Obstacles to implementa-
tion of miniaturized screening have included high instru-
ment cost and unacceptable reliability or performance of
either the instruments or the assays in the 1536 well
format. To accomplish miniaturization of cell-based
assays, GNF has taken an industrial approach to building
a de novo screening system. Modi® cation to oå -the-shelf
instruments resulted in reliable nanoliter dispensing to
1536 well plates. Unique solutions well developed to
reduce evaporation and edge eå ects in 1536 well plates.
To maintain versatility, custom compound and assay
(cell) plate storage solutions were developed.
A novel nanoliter ￿ uid transfer system
Chris Shumate, Mitch Dotktycz, Oak Ridge National Labora-
tory, Oak Ridge, TN
A novel, low volume transfer system has been designed
and tested in a variety of con® gurations. The system
consists of a precision micro¯ uidics coupled to high-speed
valving and pressure delivery. Volumes of 5 nanoliters to
multiple microliters can be rapidly transferred in a highly
parallel manner. The system can be con® gured for
reagent delivery and sample transfer and oå ers the
bene® t of size, economy, and robust performance. Poten-
tial uses include library replication, sequencer and
synthesizer applications, micro-array production, and as
enabling middle-ware for microplates and lab-on-a-chip
integration. Various con® gurations, their use scenarios,
as well as performance speci® cations will be presented.
384-well small volume microplates: a new plat-
form for approaching the 2 to 10 mL range?
Guënther Knebel; Greiner Labortechnik GmbH, Frickenhausen,
Germany
The success of the 1536 well plate has encouraged us to
investigate other user-friendly plate formats in the 2 to
20mL range which oå er similar savings in reagents at
lower investments. A novel 384 well small volume (SV)
microplate with a total well volume of 30mL saves
reagents and reduces costs per well signi® cantly without
major changes in robotics and liquid handling.
An optimized well shape combined with a properly
adjusted Z-axis of the plate reader can improve the signal
strength in these small volume microplates. Sensitivity
of 384 and 1536 well plates is very similar in the 2 to
20mL range and enables us to perform homogeneous,
heterogeneous, and cell based assays. Various cell-based
assays have been investigated in black tissue culture
treated plates by monitoring ¯ uorescence in a CyQuant
assay.
The data presented compare the properties of 384 SV
and 1536 well plates in the sub 10mL range and highlight
the impact of the appropriate imaging systems and plate
readers.
An automated liquid–liquid extraction system
utilizing interface detection and supervised by an
industrial programmable logic controller
Stephane Bostyn*, J. Gaucher*, G. Christophe*, R. Soukehal*
and C. Porte**: *Laboratoire de Productique ChimiqueöIUT-
Universite è d’Orle è ans, Orle è ans, France, **Laboratoire de Chimie
Industrielle du Conservatoire National des Arts et Me è tiers, Paris,
France
In the case of the development of new products in organic
synthesis, the ® nal step of the process must oå er the best
purity. In this way, the ® nal step is a unit operation of
isolation like distrillation, crystallisation or liquid± liquid
extraction. Therefore, it is necessary to integrate module
of puri® cation on an automated platform for achieving
the whole process.
In our case, an automated platform was based on a
robotic Zymark architecture allowing us to make sample
preparation and the reaction steps. For the puri® cation
module, we opted to develop our own home liquid± liquid
extraction module. This unit operation permits us to
separate the ® nal product in the case of liquid phase
peptide synthesis in, but equally, in the case of isolation of
vegetal molecules.
The module capacities had to permit the multistage
extraction and the determination of the binodal curve
for optimising the process, and to possess in own system
for liberating the Zymark robot for other tasks. This
system is an industrial PLC (Omron) which manages the
whole steps of extraction. The PLC is connected by
Zymark system by logical inputs and outputs.
For carrying out these requirements and in order to have
a low cost, a classic laboratory funnel is used on which an
electrovalve is implemented at this bottom. The Zymark
arm brings the reactor to the module and quantity of
extraction solvent is introduced by MLS. Afterwards, the
mixing is made by bubbling. Finally, a capacitive
detector allows the detection interface. After this opera-
tion, the phases are oriented owing to several electro-
valves ® rst for analytical sample and after for storage. In
position of storage, a new step can restart in function of
the operator parameters.
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designed experiments in organic chemical process
research and development
Gary S. Proehl, Eisai Research Institute, Andover, MA
With the advent of High-Throughput Screening (HTS),
the process research chemist in the pharmaceutical
industry has seen two major changes. First, the increased
number of lead compounds being generated by HTS is a
challenge for the process development chemist doing
synthetic route optimization. Second, the multi-position
reaction equipment used by HTS is an opportunity for
performing parallel chemical reactions. Combined, these
changes beckon a new approach to process chemical
R&D.
This presentation will describe work using statistically
designed experiments performed on a 12-position array
reactor. This methodology can rapidly and eæ ciently
® nd optimal parameter settings for a chemical reaction.
Using this approach, chemists in process R&D can
address the challenge of an increasing workload while
delivering improved chemical reaction conditions.
Automation in process development: the P￿ zer
robotic experimental design system (RED)
Neal Sach*, P. Higginson*, P. Hailey*, A. Pettman*, J.
Wallis**, *Pharmaceutical Sciences, P¢zer Global Research
& Development, P¢zer Ltd., Sandwich, Kent, **Logic Rapid
Ltd., Chestnuts House, West By£eet, Surrey, UK
Statistical design of experiments is a simple but powerful
tool for planning experimental investigations to extract
the maximum amount of information with the most
eæ cient use of resources. The technique is particularly
applicable for commercial route optimization, process
parameter setting and process robustness where there
are huge business bene® ts to be gained. Until recently
however, this approach has been tedious and potentially
inaccurate due to the large number of experiments that
were performed by hand and the high level of quality
required.
P® zer (UK) Process Research and Development has
sought to combine technological innovation with experi-
mental design to facilitate eæ cient process optimization
of late stage candidates. A robotic system was designed,
in collaboration with Zymark (UK), to closely model
commercial plant capability whilst allowing high
throughput of reactions with the additional quality
automation oå ers.
Two plant reactor mimics and peripheral modules were
designed and integrated with a Zymark XP Track
Robot. Throughput limitations of two reactors were
resolved by incorporating automated self draining/self
cleaning modules into the system to allow 24/7 operation.
LECIS based control software was written in-house
allowing simple high quality, reproducible control.
The presentation will focus on the design and develop-
ment of the system with real examples of the system
success as a total automated solution to experimental
design.
Using automation to achieve compliance in R&D
and QC laboratories
Ronald F. Tetzla¡, KMI/PAREXEL, LLC., Alpharetta, GA
Most R&D and QC laboratories use Laboratory In-
formation Management Systems (LIMS) to capture,
analyze, and maintain the large amounts of analytical
data that are needed to comply with current Good
Manufacturing Practices (cGMP) Regulations. Even
with the use of LIMS systems for managing the data,
quality professionals face some formidable challenges
when trying to establish and maintain systems and pro-
cesses that are in compliance with the requirements of the
Food and Drug Administration (FDA). For example, a
large number of personnel must maintain an awareness of
regulatory requirements (including changes in policies
and expectations), and practical ways are needed for
determining whether the facilities, systems and processes
have achieved a state of compliance.
A consultant’ s perspective will be presented about ways
to use automation to improve the communication of
information about performance of the various systems
and processes. This discussion will take into account the
communication barriers that are created by the diverse
organizational structures, including the con¯ icting re-
sponsibilities that are inherent between R&D and QC
departments. Presented will be some practical ways to
use automation in ways that will allow responsible
management to be aware of the regulatory expectations.
Automated tools should be designed to ensure that
responsible personnel have available suæ cient data about
the performance of the systems and processes, and the
information must be presented in a manner that key
personnel will be able determine whether data and
information are in accordance with the regulatory re-
quirements. Automated tools should be designed to
ensure that personnel know the boundaries of their
responsibilities, and to document the basis for their
judgments and decisions. The quality systems used in
the healthcare industry have reached a level of diversity
and complexity that necessitates new ways of using
automation in R&D and QC laboratories.
Re-testing in the regulated laboratory
Jean Blackston Hill, U.S. FDA, Philadelphia, PA
The TridentTM multiple parallel synthesizer by
argonaut technologies as a workhorse in an inte-
grated automation environment
Richard A. Wildonger, Chemical Technology Section, Enabling
Science and Technology Department, AstraZeneca Pharmaceuti-
cals, Inc., Waltham, MA
Critical to the eå ective implementation of high through-
put methods of synthesis is the necessity for a signi® cant
supporting level of automation. There are a number of
critical issues associated with the successful introduction,
and supporting role, of automation of small molecule
chemical synthesis. Clearly there are needs for automa-
tion to increase drug candidate synthesis throughput.
Automation of repetitive and laborious tasks associated
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apply their talents to the more challenging investiga-
tional aspects of developing new synthetic protocols. This
provides continuity in the compound supply pipeline and
ensures an optimal use of the automated platform for
compound production. The very high ® delity of perform-
ing repetitive processes that can be managed through
automation also removes some of the limitations and
errors associated with more fallible human operators.
This can include very diæ cult tasks associated with
tracking data, and general information and inventory
management. Taken collectively, these attributes associ-
ated with automation can lead to greater eæ ciencies,
throughputs and improved allocation of human resources
with concomitant reductions in costs associated with
current day and future drug discovery.
In our library development/synthesis paradigm we feel
that automation support must be invoked early in the
process and that this automation support must continue
throughout the project. One key component of our
automated Multiple Parallel Synthesis capability is the
TridentTM automated synthesizer by Argonaut Tech-
nologies. In this talk we will focus on the role that the
TridentTM plays in our Chemical Technology group as
libraries are brought to fruition.
Automation in high throughput chemistry
Bill MacLachlan, SmithKline Beecham, Essex, UK
Successful high throughput chemistry in a drug discovery
environment requires the strategic use of automation.
Pressures are ever increasing to prepare rapidly diverse
drug like compounds in good purity to satisfy the
demands of high throughput screening and genomics.
In addition to aiding the preparation of large collections
of compounds for lead generation, automation must be
applied to lead optimization to attain fully the eæ ciencies
required in the complete drug discovery process.
The successful automation of medicinal chemistry re-
quires the prudent use of a range of platforms to perform
synthesis, analysis and puri® cation of target molecules.
The devices and processes must cope with the production
of compounds of diå erent physicochemical properties in a
variety of scale. Most importantly, the automation must
be suitable to be used by the skilled medicinal chemist as
a routine tool to exploit fully their creativity and craft.
A discussion of key automated devices and their integra-
tion will be presented.
Extending the range of executable automated
chemistries available to the Zymate XP synthesis
system
David A. Rudge, AstraZeneca UK, Maccles¢eld, Cheshire, UK
Automated Chemistry has been undertaken in the High
Capacity Synthesis Laboratory at AstraZeneca’ s Alder-
ley Park Research Laboratories using the ZymateXP
Synthesis Robots since 19921;2;3. During this time over
80 diå erent synthetic procedures have been undertaken
involving over 30,000 reactions.
One of the aims of the High Capacity Synthesis Group,
alongside the provision of an automated chemical syn-
thesis service, has been to disseminate chemical tech-
nologies into the general synthesis laboratories. This has
been ahieved using, in part, the BenchmateTM Work-up
System, developed in collaboration between our labora-
tory and Zymark UK.4;5
With an enabling technology available to the general
synthetic chemistry community, we have determined to
develop the ZymateXP Synthesis Systems to undertake
higher capacity synthesis, both in numerical terms and
also that of scale.
We have also started to develop the capabilities of the
systems further to enable the execution of a broader
range of more challenging synthetic methods which, at
present, are not possible using the range of automation
available in the general synthesis laboratory.
We will describe the use of a solid addition station to
facilitate the addition of insoluble reagents, the use of
septum piercing hands for reaction set-up and reaction
sampling under inert conditions and the ability to
execute low temperature chemistry.
These developments have been undertaken against a
backdrop of an evolving Visual Basic front-end to the
Zymate Easylab Software to allow for a ` walk-up’
approach to the technology.
(1) Automated Chemical Synthesis. Brian G. Main and
David A. Rudge, p. 425. Proceedings of the Inter-
national Symposium on Laboratory Automation and
Robotics 1994.
(2) The creation of an Integrated Data handling System
for Automated Organic Synthesis. C. Green, p. 164.
Proceedings of the International Symposium on
Laboratory Automation and Robotics 1996.
(3) Development of Workstations for Filtration and
Puri® cation of Samples Prepared by Automated
Synthesis. D. Rudge and M. Crowther, p. 264.
Proceedings of the International Symposium on
Laboratory Automation and Robotics 1997.
(4) A Versatile, Fully Automated, Open Access Work-
Up Station Designed to Serve the Needs of the
Rapidly Expanding Field of Multiple Parallel Syn-
thesis. G. A. Hamlin. Proceedings of the Inter-
national Symposium on Laboratory Automation
and Robotics 1998.
(5) A Compact, Fully-automated Solution-phase Reac-
tion Work-up Facility for Multiple Parallel Syn-
thesis. G. A. Hamlin. Proceedings of the
Internationl Symposiium on Laboratory Automation
and Robotics 1999.
cAMP-ScreenTM: cellular cyclic AMP quanti￿ ca-
tion in an automated 384-well format
Anthony C. Chiulli, Tropix/Applied Biosystems, Bedford, MA
The second messenger, 30,50-cyclic AMP (cAMP), is a
highly regulated molecule that is governed by G protein
coupled receptor activation and other cellular processes.
Measurement of cAMP levels in cells is widely used as an
indicator of receptor function in drug discovery applica-
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the accurate quantitation of cAMP levels produced in
cell-based assays. This novel competitive assay utilizes
chemiluminescent detection that aå ords both the sensi-
tivity and the dynamic assay range that has not been
previously reported with any other assay methodologies.
The assay has been automated in 96- and 384-well
format, providing assay data that is equivalent, if not
better, than data generated by hand. Our data indicates
the feasibility of utilizing this assay methodology for
monitoring cAMP levels in a wide range of functional
cell based assays for high throughput screening.
Putting sheet screening into practice at Abbott:
ramping up a new screening technology
James Kofron, Lawrence Vernetti, Steven Anderson, Patrick
Hymphrey, Carol David, Martin Voorbach, Jennifer Donnelly,
Xiaoling Xuei, Yihong Fan, Sujatha Gopalakrishnan, Uha
Warrior and David Burns, Abbott Laboratories, Abbott Park, IL
Abbott’ s Continuous Format High Throughput Screen-
ing (CF-HTS, sheet screening) is a novel, high-density
screening platform based on a well-less array (8640) of
compounds and gel assay technology. This high through-
put screening format has all of the advantages associated
with miniaturization (e.g. low reagent consumption, low
cost) while providing several advantages over other high-
density plate screening (heterogeneous and homogeneous
assays; no evaporation, liquid handling, or edge eå ect
issues; minimal automation requirements). Abbott has
used this technology for production screening since mid-
1998, and is ramping up and extending this technology in
pursuit of a goal to run half of our activity-based screens
in this format by the end of 2000. The basic technology
behind CF-HTS will be presented with several diverse
assays as examples, and the modi® cations to our screen-
ing infrastructure to support this eå ort will be discussed.
We will present our current plan to resolve bottlenecks in
the areas of data reduction, compound cherry-picking
and reformatting, gel manipulation, and imaging
systems.
Laboratory 2000: the challenge of achieving e‡ -
ciency and compliance
Alan Potter, GlaxoWellcome, Zebulon, NC
Signi® cant advances within the ® eld of laboratory auto-
mation and instrumentation have greatly bene® ted the
pharmaceutical industry in its quest to discover, develop
and monitor the quality of its products. Necessitated by
the need for eæ ciency and greater productivity; faster
and more cost-eå ective means of analyses exist in the
form of devices made up of complex electro-mechanical
components, all logically controlled and most with the
capability to interface with sophisticated information
systems. This bene® t does come with a price, a greater
responsibility to ensure data quality while complying
with increased regulatory requirements. Commitment
to this responsibility presents a substantial challenge to
scientists and managers throughout the industry. Due
diligence must be demonstrated. A comprehensive evalu-
ation of every laboratory system utilized, a solid plan of
action for correcting any known de® ciencies including
upgrades or complete replacement, and an accurate
monitoring procedure with the ability to measure pro-
gress are all absolute necessities to ensure success. Cross-
functional term eå ort and communication must transpire
with full managerial support. Vendors need to be
audited, made aware of any functional or quality in-
adequacies they possess as well as the pharmaceutical
industry’ s expectation for these shortcomings to be
rapidly corrected. Suppliers of these systems should also
be encouraged to provide complete ` oå the shelf sol-
utions’ to eliminate the need for in house customization.
The requirements for regulatory compliance in today’ s
electronic environment have been well publicized. The
players involved are not only listening, but also taking
the necessary steps to retain and improve eæ ciency
without sacri® cing quality. With the proper measures,
planning and action; a highly automated, cost eå ective
and compliant laboratory operation can become a
reality.
Building an electronic data/compliance foundation
utilizing wireless eClipboards
Mike Stroz, AstraZeneca Pharmaceuticals, Westborough, MA
The pharmaceutical industry is rapidly transitioning to
¯ exible, multi-site global organizations operating under
demanding regulations. Eå ective information manage-
ment provides a foundation for high productivity, rapid
response, and regulatory compliance. The industry can
no longer rely on today’ s combination of paper and
electronic records. Astra Zeneca has incorporated the
VelQuest ePMCTM (electronic Process Management and
Compliance) system to address these issues and more.
The ePMCTM provides primary data capute at the
source creating valid electronic records, and linking these
records to the procedures from which the data was
created. This electronic platform facilitates compliance
with cGMPs and 21CFR Part 11.
My continuing adventure with 21CFR Part II: the
evolution of Zymark's compliance
Stephen Dobro, Zymark Corporation, Hopkington, MA
A renewed focus has been given to the three year old
regulation, 21CFR Part 11. The speaker will present a
chronology of the process of validating a previously
developed and commercially available instrument for
compliance to 21CFR Part 11. This will include all
aspects of the exercise which include familiarization with
the standard, development of the protocols, review of the
protocols by industry experts, pharmaceutical user com-
pany review, execution, exception reports, and any
necessary product revisions. Zymark’ s TPWII rev 2.0
was chronicled because it has been recently developed
and reasonably expected to meet the requirements of
21CFR Part 11.
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quantitative determination of Simvastatin-derived
HMG-CoA reductase inhibitors in human plasma
using a Tecan genesis 200 robotic workstation
combined with 96-well plate technique
Wei Fang, L. Liu, J.Y-K Hsieh, J. Zhao, J. D. Rogers, B. K.
Matuszewski, M. R. Dobrinska, Merck Research Laboratories,
Merck & Co., Inc., West Point, PA
The cholesterol-lowering drug simvastatin (SIMV) re-
duced heart attacks by 42% in patients who had high
cholesterol levels and suå ered from heart disease. Upon
oral administration, SIMV is quickly hydrolyzed to its b-
hydroxyacid (b-HA) and other acid metabolities, which
are potent inhibitors of 3-hydroxy-3-methylglutary l
coenzyme A (HMG-CoA) reductase.
Over the last 10 years, Tecan single-probe and Zymark
single-tip robots have been used to perform an enzyme
inhibition assay for the determination of the concentra-
tion of HMG-CoA reductase inhibitors in human plasma.
Although both robots do relieve the analyst from per-
forming some tedious, repetitive, and time-consuming
tasks, low sample throughput, frequent analyst’ s inter-
vention, and mechanical instability were observed. This
enzyme inhibition assay has recently been modi® ed to
achieve higher sample throughput and improve assay
reproducibility and mechanical stability by taking ad-
vantage of 96-well plate technologies and a Tecan
Genesis 200 robotic workstation equipped with 8 ® xed
tips and some customized hardware and accessories.
The modi® ed assay was validated over the concentration
ranges of 0.4 to 20 ng/mL, and 2 to 50ng/mL for SIMV
and b-HA. Intraday precision values (C.V.) for replicate
analysis …n ˆ 5† of standard curve samples were less than
5 and 9%, respectively. Intraday accuracy ranged from
95 to 105% of nominal value for the two concentration
ranges studied. The interday precision of the quality
control (QC) samples was less than 2 and 8%, respect-
ively. The respective interday QC accuracy values were
93 to 103% and 97 to 104%. Good linearity across the
two concentration ranges was obtained with acceptable
reproducibility. This validated assay has been utilized to
analyze human plasma samples from several simvastatin
clinic studies. Full details of the assay methodology will
be presented.
Robotic system for handling infectious clinical
and pre-clinical serum samples
David Pechter, Robert Firman, Jun Chen, Eric Chaplin,
Schering-Plough Research Institute, Union, NJ; Eugene Lochart,
The Baker Company, Sanford, ME; Rick Johnstone, Schering-
Plough Research Institute, Union, NJ
The Bioanalytical Laboratory at the Schering-Plough
Research Institute is a service laboratory which performs
drug level measurements in serum in support of pre-
clinical toxicological tests, as well as human clinical trials
for anti-viral compounds. A new robot system for the
laboratory had two external constraints put on it, besides
those typical for a robotic system: since it handled
infectious serum samples, it needed to be contained
within a biosafety cabinet, and all data handling and
labelling were subject to regulatory oversight. The result
is a robot cell consisting of a large custom biological
safety hood with an integrated track mounted robot,
refrigerated storage, mixing, 2-D bar code reading, and
automated pipetting. In addition to the material hand-
ling hardware, sample labelling software was developed
for use at sample collection sites within Schering-Plough,
and at external contract laboratories.
Automated dual LC/MS/MS system doubles the
sample throughput of a single mass spectrometer
Larry S. Birkemo, Stephen A. Wring, Lloyd Frick, Jonathan B.
Morgan, Jimmy Bruner, James Ormand, Glaxo Wellcome Inc.,
Research Triangle Park, NC
In vitro drug discovery screens generate large numbers of
samples for analysis and have a pivotal role in accelerat-
ing drug discovery. To keep pace with the need for
increased bioanalytical capacity, we have developed an
automated dual LC/MS/MS system that doubles the
sample analysis capacity of a single mass spectrometer.
In a typical LC/MS/MS chromatographic run, the ¯ ow
path is diverted to waste at the beginning and end of the
run, resulting in idle time for the mass spectrometer. We
synchronized the injection of samples into two HPLC
systems and their ¯ ow paths such that when the ¯ ow
from one system is being diverted to waste, the ¯ ow from
the other system is being analyzed by the mass spectro-
meter.
Dual LC/MS/MS was performed using two HP1100
binary pumps, a 6-port switching valve, 2 chromato-
graphy columns, and a Gilson 215 autosampler
(equipped with 2 Gilson 819 injection ports) interfaced
to a PE Sciex API2000 mass spectrometer.
Integrated control of the timing of sample injections,
column-switching, and start of the pump gradients was
achieved with customized HP Chemstation macros and a
Visual BasicTM application. Customized user-input
screens were accessed by menu choices added to the
standard Chemstation user-interface.
The system has proven to be robust: >5000 chromato-
grams have been generated without failure. Use of dul
LC/MS/MS results in a 2 fold improvement in sample
throughput. Combined with other techniques (e.g., cas-
sette analysis or fast gradient chromatography), up to a
16 fold improvement in productivity vs traditional LC/
MS/MS has been achieved routinely in our laboratory.
A validated automated sample preparation for Lc/
Ms/Ms to facilitate a multi-step extraction for
analytes of di´ ering polarities from plasma
John R. Kagela, Rupinder Bhamrab and Christine Swensonb,
aPrimedica Corporation, Worcester, MA and bThe Liposome
Company, Princeton, NJ
An LC/MS/MS method, using automated sample pre-
paration for the isolation of potentially unstable drug and
multiple metabolities from plasma, was validated and
used for sample assays. Due to the polarity range of the
analytes, it was not possible to extract each analyte in
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group of analytes with similar polarities was isolated from
plasma (Step 1) using a liquid-liquid extraction. The
organic layer was removed and evaporated. Next (Step
2) the remaining group of analytes was isolated using a
protein precipitation. The organic layer from Step 2 was
added to the residue from Step 1 and evaporated. After
reconstitution and centrifugation, the supernatant was
transferred to injection plates for assay of all analytes in a
single run. The diå erences in extraction conditions also
were re¯ ected in comparable diå erences in optimized
LC/MS/MS conditions. Therefore, it was considered
advantageous to use separate analog internal standards
for analytes from each of the two extraction steps.
Automated parallel processing for the multiple transfer
steps was used to increase throughput signi® cantly.
Summary statistics for the three days of validation will
be reported.
Speeding metabolic stability assays using auto-
mated, high throughput LC/MS techniques
Kelly Johnson1, J. Erve2, A. Dandeneau2, M. Swartz1,
B. Kenney1, 1Waters Corporation: Milford, MA, 2GENTEST
Corporation: Woburn, MA
In drug discovery, metabolic stability is often a key factor
in whether or not a compound continues on in the
development process. Metabolic stability can be assessed
in vitro using pooled liver microsomes obtained from
humans or other species of interest. To meet the growing
demand for rapid analysis of the large number of samples
generated by metabolic stability assays, automation has
become necessary to increase sample analysis. The use of
LC/MS analytical methods can provide the required
selectivity, sensitivity, and speed to produce quality data
rapidly.
This presentation will demonstrate the use of LC/MS to
measure samples produced in a metabolic stability assay.
Taking advantage of such factors as parallel sample
processing, high sample capacity, and shorter columns
to reduce cycle and analysis times, we can analyze the
large number of samples produced, and ultimately help
expedite the drug discovery process.
Increasing productivity through a combination of
automation and robotics: a case study of assay
services
Melissa L. Cheu, Genentech, Inc., South San Francisco, CA
The Assay Services Department at Genentech, Inc. is a
service laboratory that performs drug level measurement
and antibody testing in support of pre-clinical animal
studies and human clinical studies. As the number of
Genentech products has increased, so have the number of
studies, resulting in an annual increase in the number of
samples generated and an increased demand for assay
support. Assay Services has addressed this by increasing
the eæ ciency and productivity of sample handling and
assaying through the automation of various procedures.
All sample dilutions are now done by automated dilutors,
reducing the number of reassays and virtually eliminat-
ing the repetitive stress of manual sample dilutions. In
addition, two complete ELISA robot stations have been
in use over the last two years that have increased
throughput by increasing the number of plates per run
(10± 15 96-well microtiter plates), and by allowing assays
to run overnight without requiring the presence of lab
personnel. The net gain from the automation eå orts has
been to double to number of samples run without
increasing the number of lab personnel.
Automation of an SPE HPLC assay for atenolol
levels in human serum
Joe Long, Gleen Smith, Jimmy Bruner, James Ormand, Glaxo
Wellcome Inc., Research Triangle Park, NC
To increase productivity in the bioanalytical laboratory,
we have combined several automated steps, from speci-
men tube log-in and handling to extraction and HPLC
injection, to make the process as hands-free and eæ cient
as possible. These steps combine the advantages of time-
saving with safety, allowing less exposure to biohazards
and laboratory chemicals.
This poster will discuss the steps in developing an
automated method for analysis of Atenolol in human
serum. The method was developed to support clinical
trials involving a new anti-diabetes drug at Glaxo Well-
come. Atenolol is a selective b1-adrenoceptor antagonist
used in the treatment of hypertension. Since many people
with diabetes are also taking anti-hypertensives, this
study was conducted to determine the eå ects and safety
of this combination.
Automated sample handling involves the use of preas-
signed barcoded specimen tubes of a speci® c size. Tubes
are scanned into a bioanalytical spreadsheet, arranged
into racks then placed on tube uncapper/capper instru-
ment. After uncapping, the rack is positioned on the
Tecan deck that is part of a combination Zymark/Tecan
96-well sample prep robotic system. When sample ex-
traction is complete, the 96-well plate is placed in an
autosampler and run overnight.
Other systems available in our laboratory include one
with the capability of transferring small volume samples
into 96-well plates, with gravimetric con® rmation. Mass
spectrometry is also used, allowing shorter run times and
more speci® c compound identi® cation.
Automated protein precipitation in a 96-well
microtiter ￿ lter plate
Beth A. Boman and Robert Pranis, 3M Filtration Productsö
Empore, Mendota Heights, MN
Emerging bioanalytical trends are demanding that dis-
covery, metabolism and clinical groups analyse a greater
number of compounds in a shorter amount of time.
Sample preparation is now the rate-limiting step to
achieving higher throughput. Protein precipitation in a
3M Empore
1 96-well microtiter ® lter plate automated
on a Beckman Biomek
1 2000 Workstation oå ers rapid
sample preparation for the analysis of drugs and meta-
bolites in biological ¯ uids.
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1 2000 Workstation oå ers many features
that reduce the risk of error and improve productivity.
Pipetting, diluting and dispensing operations are per-
formed quickly, easily and automatically. The 3M
Empore Filter plate removes precipitated proteins by
a 3M patented graded density ® lter composed of
polypropylene. The product has been experimentally
determined to retain 98% of all particles larger than
10mm in size.
The Biomek
1 2000 Workstation performed sample
transfer and internal standard addition to the samples.
The protein precipitation and sample ® ltration occurred
on the ® lter plate with vacuum from the online vacuum
manifold with simultaneous sample collection. The
® nal step to the sample preparation was addition of a
mobile phase compatible buå er to make each sample
ready to inject. The samples were analyzed via HPLC
and the recovery and reproducibility results are
reported.
Determination of drug permeability by ￿ lter-
immobilized arti￿ cial membranes and detection
by LC/MS
Konstantine Tsinman1, E. H. Block2, A. Avdeef 1,
M. Stra¡ord1, B. Kenney2, M. Balogh2, K. Yu2, 1pION, Inc.
Woburn, MA, 2Waters Corporation, Milford, MA
Prediction of oral obsorprtion properties of lead com-
pounds is a tool that can help discovery teams make the
decision of go, no no, or repair prior to candidate
selection. A new in vitro model of permeability based
upon ® lter-immobilized arti® cial membranes composed
of phospholipids was combined with an LC/MS detection
method. Well-characterized compounds and extracts of
the kava plant (lactones) were processed through the
decribed system and compared with results from detec-
tion by UV spectrophotometry. In addition, a cassette
experiment of ® ve of the lactones was performed and
comparison made to values for the individual com-
pounds.
Methods. A series of model compounds and extracts of
the kava plant were processed with a pION PSR4p
instrument, and their permeabilities were derived from
diå erential UV absorption. The same samples were
additionally analyzed using a generic HPLC/MS
method. Alternating positive/negative electrospray ioni-
zation in the full-scan mode was chosen as the most
applicable interface and scan regime. Following data
acquisition, the resulting data were processed and a
variety of quantitative and qualitative information was
obtained.
Results. Permeability coeæ cients based on relative LC/
MS peak areas for each analyte compared favorably with
those obtained by UV determination. In addition,
similar results were obtained even when the compounds
were present as a mixture. HPLC/MS detection also
allowed for limited identi® cation of unknown compon-
ents in supposedly ` pure’ standards.
Performance of the AtheNA Multi-Lyte ANA test
system; a homogeneous, microparticle-based mul-
tiplexed ANA test system
Mark Kopnitsky, M. Connelly, D. Rran, K. Cichonski,
J. Torres, G. Lin, J. Hablawai, M. Desiderio, Zeus Scienti¢c,
Inc., Raritan, NJ
A study was conducted to assess the performance of a
commercial, ¯ ow cytometry-based microparticle system
for the simultaneous detection of thirteen diå erent anti-
nuclear antibody (ANA) speci® cities. Recombinant or
aæ nity puri® ed proteins (SSA, SSB, Sm, RNP C, RNP
68, RNP A, RNP BB0, Scl-70, Jo-1, Centromere B, and
histones) were covalently bound to the surface of dis-
tringuishable polystyrene microparticles. Antigen-speci® c
microparticle sets were mixed to form a multiplexed
ANA substrate. Patient sera were evaluated for the
thirteen diå erent speci® cities simultaneously in a homo-
geneous assay format. Sera from 119 normal blood
donors were used to evaluate assay speci® city and sera
from 110 clinically characterized autoimmune patients
were used to assess assay sensitivity. ANA HEp-2 indirect
¯ uorescent assay (IFA) was used as the reference method.
Individual commercial ELISAs were used to resolve
discrepancies. In the normal donor group, concordance
to ANA HEp-2 was 87.2%. Of the 15 discrepancies,
11/15 (73%) were negative on the AtheNA assay and
positive by IFA. In the autoimmune group, concordance
was 89.1%. Of the 12 discrepancies, 8/12 (67%) were
positive on the AtheNA assay and negative by IFA.
Following the resolution of discrepant specimens, the
percent sensitivity, speci® city and agreement relative to
IFA was found to be 98.8%, 92.9% and 97.3% respect-
ively. We have concluded that the AtheNA Multi-Lyte
ANA Test System provides a homogeneous, multiplexed
objective means to detect speci® c ANA with sensitivity
and speci® city comparable to that of ANA HEp-2 IFA.
Protein bound drug binding determinations with a
96-well ultra￿ ltration device for ADME applica-
tions
Aldo M. Pitt, Sara Gutierrez, and Micky Tortorella*, Millipore
Corporation, Danvers, MA, *DuPont Pharmaceutical Co.
Wilmington, DE
A critical parameter required as part of ADME screening
is the determination of small molecule binding to serum
proteins. Traditionally, these measurements have been
determined by equilibrium dialysis techniques with ultra-
® ltration used as an accepted alternative method. Both of
these methods have been time consuming and tedious
since single devices had to be handled. The purpose of
this report is to characterize a new 96-well ultra® ltration
device for its low binding properties and also to directly
compare the protein binding results achieved to equal-
ibrium dialysis. The use of a new low binding plastic
demonstrated increased compound recoveries even when
directly compared to polypropylene. A correlation coeæ -
cient of 98% was calculated when the equilibrium
dialysis and 96-well ultra® ltration binding results were
compared. The 96-well ultra® ltration device provides
comparable results to equilibrium dialysis with the speed
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throughput ADME screening.
Evaluation of bias observed with the Zymark
MultiDose automated system
Gale Grant, P. St.-Laurent, C. Briand, A. Dillolo, E. Kwong,
J. Visentini, S. McClintock, Merck Frosst Canada & Co.,
Montreal, Canada
The eå ect of the cannula size of the Zymark MultiDose
dissolution system on the dissolution rate for two drug
formulations was evaluated. A bias towards a higher
dissolution rate was observed for results generated on
the automated MultiDose system compared to results
obtained from the manual dissolution method. The bias
was more obvious for the lower strength dosage forms at
lower paddle speeds. Several experiments resulted in the
conclusion that the bias toward higher results with the
automated system was due to the additional disturbance
caused by the presence of the sipper cannula during the
sampling period. There is a signi® cant diå erence in the
external diameter of the MultiDose cannula (containing
thermistor) and those used as USP manual cannula. As
well, the cannula on the MultiDose system remains in the
media for a longer period of time during sampling due to
the maximum allowable ® ltration ¯ ow rate of 12ml/min.
As a result of this bias, a prototype MultiDose head that
consists of two modi® ed stainless steel cannula, one for
drawing sample and the other as a thermistor, with
similar internal and external diameters to standard
cannula used for manual dissolutions was evaluated with
the two drug formulations. The data generated with this
system was comparable to the manual methods in
contrast to data generated with the original MultiDose
sipper cannula.
Streamlining the dissolution test: automated
HPLC techniques
Kelly A. Johnson, Michael E. Swartz and Patricia A. Fowler,
and Charles H. Frasier, Waters Corporation, Milford, MA
The fast pace of the modern pharmaceutical industry
requires laboratories to reduce the analytical burden of
their test procedures, and increase productivity while still
satisfying regulatory compliance. There are now several
ways to meet these challenges in the dissolution labora-
tory. Automated dissolution systems eliminate the slight
variations that may occur in manual methods, thereby
insuring reproducible data, higher throughput, and cost
reduction. Validated single source software control of the
entire automated system, as well as dissolution data
acquisition and calculations, can further streamline the
work ¯ ow while maintaining FDA compliance, as with
21 CFR Part 11. As a signi® cant time and resource saver,
the USP now approves several methods that involve the
analysis of pooled dissolution samples, in which indi-
vidual dissolution aliquots are pooled and assayed as a
single sample. Modern on-line HPLC dissolution systems
can pool the individual samples and perform these types
of analyses automatically, unattended. Similarly, the
ability to automate sampling at shorter intervals and
analyse a large number of samples via an on-line HPLC
system may provide a more complete solution for the
decision making process in the early stages of drug
development. Also, these systems must also be capable
of handling increasingly complex formulations, such as
multiple actives, widely varying dosages, as well as media
types being used, such as buå ers, organic solvents, and
surfactants.
We will present data generated by a single hardware and
software source for a number of the above pharmaceu-
tical dissolution applications, summarizing a complete
approach to reducing the analytical burden and increas-
ing sample throughput in the dissolution laboratory.
Development of a TPW II sample preparation
method for assay, impurity, CU and D-isomer
for Levaquin tablets
Suman Sharma, Steven Lum and Yolanda Scypinski, Ortho-
McNeil Pharmaceutical, Raritan, NJ
A TPW II method for Levaquin Tablets was developed
for the sample preparation of 250mg, 500mg and 750mg
tablets. The original manual sample preparation method
involves soaking ® ve tablet in the diluent for 30 minutes,
shaking for an additional 30 minutes followed by settling
the sample solution for one hour. A dilution step is
required after settling. Using the new TPW II method
has reduced the sample preparation time by half and has
increased the accuracy and precision of the method.
This poster primarily discusses the TPW-II method
development stages, the problems encountered and the
resolutions to the problems.
A new consolidated method was also developed and used
for the analysis of all the above tests for this work. The
current chromatographic procedure uses one method to
monitor potency, impurity and CU while a second
method is used for the D-isomer.
Automation of the analysis of ￿ uorides in tooth-
paste, using a Zymate XP robot system
Caroline J. Tillett and Teck M. Khong, SmithKline Beecham
Consumer Healthcare, Weybridge, Surrey, UK
A robotic system, for the analysis of ¯ uorides in tooth-
paste, has been custom designed by Zymark to
SmithKline Beecham Consumer Healthcare (SBCH)
speci® cations. The analysis of ¯ uorides within SBCH, is
a time consuming, repetitive operation. The automation
of the methodology has been shown to deliver several
bene® ts:
. Greater throughput in processing ¯ uoride analyses.
. Increase in quality and reproducibility of ¯ uoride
analyses.
. The system is fully validated and the results are
posted to LIMS directly, with full audit trail.
. Redeployment of resources for more eå ective and
better usage.
. Reduction in analysis time by a factor of 4.5.
. 50% decrease in the cost of consumables.
Diå erent methods are performed for ¯ uoride analysis,
due to varying sample matrices and varying sources of
Abstracts of papers presented at the 2000 ISLAR
24¯ uorides and diå erent requirements of individual coun-
tries. The robot has been designed to handle all the
diå erent methods presently in use, as well as any new
methods that may be introduced. The robot prepares
samples by the speci® ed method, then analyzes by ion
selective electrode (ISE). The results are collated in a
report, which can be printed out or can be directly posted
to LIMS via a LIMSlink.
The robot has also been designed to perform the calibra-
tion of the electrode. A common problem with ISE is drift
of the electrode. The robot will analyze the drift by
measurement of a 1ppm standard in between samples,
if a drift of greater than 2% occurs the robot will
calibrate the meter, then continue reading the samples.
Automation and marketed products: a method
development case study
Christopher A. Zordan, David K. Lloyd; DuPont Pharmaceu-
ticals Co., Experimental Station, Wilmington, DE
Developing automated sample preparation methods for
marketed products raises issues not usually encounted
during ` ® rst-look’ method development activities.
Marketed products have established analytical histories
and methods. Having this knowledge allows for some
shortcuts, such as removing the need to develop and test
dilution solvents and HPLC parameters. On the other
hand, automation techniques can not exactly replicate
manual preparation methods, which may lead to extra
validation work to prove equivalence.
Coumadin
1 (Warfarin Sodium, USP) is a marketed
product within an established history of analytical
methods. An automated content uniformity method
was developed from an existing manual method and an
existing automated composite assay method. The
following points will be examined: 1) the decision to
use existing HPLC parameters to limit development
work to the sample preparation, 2) the validation of a
new standard linear response range of 0.02± 0.1mg/mL
due to a combination of dosage strength and instrument
limitations tht lead to low maximum concentrations
for the lowest dosage strengths, and 3) lowering the
internal standard concentration to 0.05mg/mL so that
it lies near the middle of the new linear range of the
standard.
MultiDoseTM dissolution testing of a moisture
sensitive product using modi￿ ed carousel caps to
control localized humidity in environment sur-
rounding tablets staged for testing
Joseph Dremock, G. Martin, D. Reed, P. Harmon, L. Magiso,
L. Fegely, Merck & Co., West Point, PA
An automated dissolution method using the Zymark
MultiDoseTM/MultiFillTM was demonstrated to be
equivalent to the manual procedure for an immediate
release drug product that has known sensitivity to
moisture. During development of the automated pro-
cedure it was determined that exposing the tablets to
the typical moisture encountered while in the carousel
above the dissolution vessel prior to testing caused the
dissolution rate of the tablets to increase at the early time
points (10, 15 and 20min.). In order to eliminate this
eå ect, carousel caps were modi® ed to include a canister of
desiccant suspended in each of the 8 wells of the carousel
while the tablets were awaiting testing. When the results
of tablets tested in this way were compared to tablets
tested manually, the mean results were within the
speci® ed acceptance criteria.
Automated sample preparation using a TPWII
compared to a semi-automated stand alone
extractor
Ron Muenz, Maria Styslo-Zalasik, John Troisi, Ronnie Mc-
Dowell and Stephen Scypinski, Analytical Chemistry Research
and Development, The R.W. Johnson Pharmaceutical Research
Institute, Raritan, NJ
A fully automated and a semi-automated sample prep-
aration procedure was developed using a ® ve tablet
composite for HPLC analysis. The automated method
uses a Zymark TPWII
1robot, while the semi-automated
method uses a Stand Along Extractor
1from Source for
Automation. Each technique uses homogenization for
tablet disintegration. Both methods were validated and
shown to be equivalent. The two methods are an
improvement over the existing manual method which
uses sonication to disintegrate the tablet. This poster will
discuss the advantages and disadvantages of each tech-
nique.
Opening the door to a ‘Paperless' laboratory
Ed Halpin, VelQuest Corporation, Hopkinton, MA
Ever increasing regulatory demnds force companies to
re-allocate resources from their primary mission to
compliance related activities. Market research indicates
that up to 70% of laboratory and QA resources are now
devoted to compliance. To ensure compliance, the
pharmaceutical industry and its partners continue to rely
on paper-based systems to achieve the required security
and audit trails. Since manual procedures cannot be fully
` validated’ , GMPs require independent checking and
approval of resulting data.
VelQuest’ s Electronic Process Management and Com-
pliance (ePMC) provides a fully validated ` paperless’
approach to acquire all data at its source, store and
retrieve this data in a fully secure database, and use this
information for new product submissions, product re-
leases, quality assurance and management analysis.
This poster will compare today’ s manual ` paper-based’
laboratory with the ` paperless’ laboratory enabled by
VelQuest’ s ePMC technology.
E‡ cient data management for accelerated com-
pound pro￿ ling
David S. Williams, Nugenesis Corporation, Westborough, MA
New technologies are producing an ocean of data, but
acting on that information is more than a few steps
behind. Certaintly, scienti® c information has value, but
having a lot of data does not mean it is worth a lot.
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in data generation technologies (high throughput screen-
ing, combinatorial and parallel synthesis) have resulted
in an unintended consequenceÐ decreased value of data
through information overload.
In theory, electronic record keeping is easy. In practice,
advanced technologies and lab applications rapidly gen-
erate a torrent of bytesÐ all products of proprietary
sourcesÐ each stored in its own proprietary ` language,’
none able to communicate with another. In the ultimate
irony of laboratory automation, the output for each
sophisticated instrument is a printed report. Converting
data into usable information requires manually piecing
together a puzzle of paper.
Nugenesis Corporation has developed a program that
systematizes the collection, storage and sharing of scien-
ti® c data by unifying it into a common electronic format.
Scientists can capture data from a variety of lab and
business application sources and store it in a central
database, while maintaining its graphic integrity. Scien-
tists anywhere in the organization can view the as-
sembled data using a web browser.
Automated moisture system
Steven J. Salata, Nabisco, Inc., East Hanover, NJ
Our laboratory’ s (Nabisco Research’ s Analytical Chem-
istry), major responsibility is testing food products in
various stages of development and stored under various
conditions to determine shelf life. Moisture content is one
of the primary chemical parameters measured. There are
a wide variety of methods for the determination of
moisture in food and the method selected depends on
the type of food being analyzed. The technique we
selected to automate is for the determination of moisture
based on oven drying. The method employs a convection
vacuum oven. Our most common matrix, cookies and
crackers are run at 708C under vacuum <50mm Hg
(6.7kPa), for 18 hours. The weight change in the sample
is reported as moisture loss. This technique was an ideal
candidate for complete automation since we analyze over
5,000 samples a year. Also the method has well de® ned
and simple steps, allowing for easy implementation as an
automated analytical process. The majority of products
run by this technique are cookies and crackers, which are
pourable and require little manipulation.
Beyond microtiter plates: molecular synthesis and
screening in arrays of microchannels
Colin Brenan1;2, Tanya Kanigan1;2, Robert Hess1 and Ian W.
Hunter2, 1Advanced Instrumentation Systems, Inc., Lincoln, MA,
2Department of Mechanical Engineering, MIT, Cambridge,
MA
In recent years, biochemical and pharmaceutical re-
searchers have begun migrating from screening in 96-
well plates to screening in 384-well or even 1536-well
plates. Screening in smaller volumes conserves space,
assay reagents, compound library reagents, and scarce
target materials. However, further reduction in well
volumes leads to the trapping of gas bubbles, rapid
sample evaporation, lower signal levels, and presents a
formidable challenge for conventional liquid handling
techniques such as pipetting.
In response we have created a novel ` nanotiter’ plate
technology with the potential to initiate and monitor
105± 106 biochemical assays in parallel with ¹100 nl total
volume per assay. Our approach purposefully exploits
the same micro-scale phenomena that cause problems
when conventional microtiter plate technology is minia-
turized without innovation in system design.
Assays are performed in uniform addressable arrays of
microchannels machined through ¯ at plates. The
through-hole dimensions are typically 200± 300mm across
and at least 500mm in length such that each channel
typically holds between 25± 100nl of ¯ uid. At these small
dimensions, ¯ uid can be transferred into the channels
from either face and retained entirely by capillary forces.
Inter-channel cross-talk is prevented through application
of an exterior hydrophobic coating to the hydrophilic
plate material. Stacking (in registration) of multiple
microchannel plates rapidly mixes ¯ uids in co-registered
microchannels within seconds through a combination of
convection and diå usion. Once initiated, all microassays
are monitored simultaneously by a low cost ¯ uorescence
imaging system based upon a cooled megapixel CCD
camera.
In addition to assays used in ultra high throughput
screening of small molecule libraries, we envision that
this technology platform will be used to perform many
other types of sub-microliter chemical or biochemical
reactions in parallel. Examples of these other applications
include combinatorial library synthesis and diagnostic
immunoassays.
Automating the determination of aqueous drug
solubility using laser nephelometry in microtitre
plates
David Proudlock, Malcolm Willson and Barbara Carey,
Glaxo Wellcome R&D. Medicines Research Centre, Stevenage,
UK
The ability to determine solubility of candidate drugs in
aqueous solution provides valuable information in the
drug development process. Nephelometry has successfully
been shown to determine this.1 This poster outlines the
implementation of a ` Solubility QC Workstation’ . The
workstation consists of the Zymark Twister, Lasystem’ s
Multidrop and BMG’ s Nephelostar. The equipment was
integrated using the ` Scrippy’ scripting software. The
validation work demonstrated good agreement with the
manual study.1 The system has been successfully trans-
ferred to the business for solubility determination of IC50
samples.
1 Bevan, C. D., Lloyd, R. S., Analytical Chemistry, 72, 2000, 1781± 1787.
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26Process improvements: increasing the throughput
and e‡ ciency of the liquid handling group at
Glaxo Wellcome
Jimmy Ballinger, Heather Judy, Brandy Lloyd and Donald
Lyerly, Glaxo Wellcome Inc., Research Triangle Park, NC
High Throughput Screening was introduced at Glaxo-
Wellcome RTP in 1996 and was initially supported by
the Compound Services Department. In 1997, increases
in the demand for liquid samples required the creation of
a Liquid Handling Group within the department. Re-
quests were ® lled using stand-alone automation and
software tools based on 96-well format. As screening
technology and capacity improved, new processes and
formats were requested by R&D scientists. The formats
included assay-ready or ` just in time’ plates from cus-
tomized dilutions, 384-well formats, pooling, column
daughters for serial dilutions, and creation of retest plates
(cherry picks). An INternational Compound Acquistion
system (INCA) was also introduced making our com-
pounds viewable and requestable by GW sites worldwide.
Due to the addition of these new work practices and the
creation of a QC department to enforce the integrity of
the liquid samples, scientists became more con® dent with
the liquid stores as shown by a 75% increase in liquid
requests over the last year and a half. The increase has
led us to evaluate the current processes and tools
employed to ensure they would be suæ cient to meet
our future needs. A Compound Services Design Team
was initiated in 1Q 2000 aimed at evaluating these needs.
The team kept in mind that we would be working with
limited resources, no additional headcount, and a ¯ at
budget. Our poster will describe process improvements
we have made or plan to make in order to increase the
group’ s throughput and eæ ciency.
The step before uHTS: assay miniaturization
using automated nL dispensing benchtop equip-
ment
M. Busch, S. Marose, T. Mander, EVOTEC BioSystems AG,
Hamburg, Germany
The bene® ts of uHTS (screening in assay volumes <5mL)
are well established: faster throughput and lower re-
agents consumption. However, surface/volume ratios
can often increase by the factor up to 100 when applying
miniaturized ¯ uid handling. Hence, adsorption of bio-
chemical reagents becomes a major issue in the perform-
ance of a miniaturized assay. Thus, special considerations
are needed to screen in the 1mL/well range. For instance
the material of the carrier and the dispensing systems
have to be considered carefully. Detergent screens or the
altering of the sequence of the addition of the reagents
can help to overcome the adsorption issues during assay
miniaturization. Several worked examples based upon
data including receptor-binding, vesicle based assays,
DNA-protein interaction and kinase/phosphatase assays
will be presented. Our results show that most of the assays
require speci® c additives for a suæ cient performance in
the micro scale. A general procedure for performing
detergent screens in an iterative mode will be discussed.
Understanding liquid handling on a Packard
Multiprobe
1II
James Ormand, Jimmy Bruner and Larry Birkemo, Glaxo
Wellcome Inc., Research Triangle Park, NC
Experimental design is a tool that can be applied to gain
an understanding of many laboratory processes such as
reaction, assay, and instrument optimization. Our auto-
mation team primarily uses experimental design to
optimize instrumentation such as liquid handling plat-
forms. Liquid handlers allow the user to optimize for
speci® c types of assays by oå ering up to 12 diå erent
parameters for controlling aspiration and dispensing.
Determination of which parameters are important for a
particular type of liquid can be a time consuming task.
In 1998, we reported on the use of experimental design to
improve the liquid handling of organic solvents on a
Tecan Genesis. This poster will compare our ® ndings on
the Tecan Genesis with the results from a current study of
liquid handling on a Packard MultiProbe
1 II. The
current study will also include examination of several
additional factors including pipet tips.
CPC microreaction technology—innovative tools
to improve the quality of organic chemistry and
to accelerate R&D processes in the life science
industry
Shahriyar Taghavi-Moghadam and Axel Kleemann, CPC Cel-
lular Process Chemistry GmbH, Frankfurt, Germany
The ® rst microreaction system now has become commer-
cially available; this innovative system provides scientists
with an advanced technology for improving and optimiz-
ing the synthetic procedures in the chemistry. The precise
control of the reaction parameters such as temperature,
reagent concentration gradient allows an explicit man-
aging of the reaction proceeding for higher selectivity and
increasing of the reaction yield.
By using a CPC modular microreaction system, a con-
tinuous process instead of batch processing, with higher
quality of reactions as a consequence of the unique
features of microreaction devices, chemists would bene® t
from the ¯ exibility in their day-to-day work. The vastly
reduced hold-up of dangerous reactants allows an easy
and safe handling of reactions with potentially hazards.
In addition, the involved time and investment would be
signi® cantly reduced. The same developed process for
small amounts of compounds in microreactors can be
used to synthesize kg- or even ton-samples in parallelized
arrays. This will lead to a higher R&D throughput and
thus to more drug candidates in the R&D pipeline.
Additionally to design and construction of microreactors
CPC focuses on the application of organic chemistry in
modular microreaction devices and will demonstrate the
feasibility and importance of this excisting new tech-
nology for the life science and the ® ne chemical industry.
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27384 well small volume plates vs. 1536 well plates:
two platforms for the 2 to 10mL range
Rainer Heller1, Anja van der Ploeg1, Johanna Neumayer2 and
Guenther Knebel1, 1Greiner Labortechnik GmbH, Frickenhausen,
Germany, 2Tecan Austria GmbH, Groedig, Austria
The progress in automation and assay detection are the
driving forces to run assays faster and in smaller volumes.
The assay volume proven to be used in further miniatur-
ization will be in the 5 to 10 mL range.
We have investigated other user-friendly plate formats
than 1536 well platforms that oå er similar savings in
reagent consumption, but with faster set-up times at even
lower investment. Finally, the well design of a standard
384 well plate has been completely re-modeled and
optimized for smaller well volumes and better detection
eæ ciency. Our novel 384 well small volume plate has
round wells with a conical well shape and a total well
volume of 30 mL (working volume between 5 and 20mL).
These plates enable to perform homogeneous, hetero-
geneous, and cell based assays. Additional features, like
raised rims per well have have added to prevent any kind
of cross-contamination.
The data presented will show that both plates have the
potential to miniaturize assays in the sub-10mL range at
the same performance. Homogeneous and cell-based
assays have been performed using CCD-imaging systems
and PMT-plate readers as detection platforms.
Disposable 96 well plastic micro￿ uidic devices for
HTS and DNA applications
A. Gerlach1, G. Knebel1, A. Guber2, M. Heckele2, D.
Herrmann2, A. Muslija2 and T. Schaller3, 1Greiner Labortech-
nik GmbH, Frickenhausen …Germany†, 2Forschungszentrum
Karlsruhe, Institut fuër Mikrostrukturtechnik, Karlsruhe
…Germany†, 3Forschungszentrum Karlsruh, Hauptabteilung Ver-
suchstechnikKarlsruhe …Germany†
Micro¯ uidic devices fabricated by mass production oå er
a wide potential of applications such as high-throughput
drug screening, clinical diagnostics and gene analysis.
The low unit production costs of plastic substrates make
it possible to produce single-use devices.
In close collaboration, Greiner Labortechnik and For-
schungszentrum Karlsruhe have developed a single-use
plastic micro¯ uidic device in the standardized microplate
footprint. Feasibility studies have shown that hot emboss-
ing with a mechanical micromachined moldng tool is the
appropriate technology for low cost mass fabrication. A
subsequent sealing of the microchannels allows sub-
microliter sample volumes in 96-channel multiplexed
microstructures. The micro¯ uidic lab-on-chip structures
are compatible with existing plate and liquid handling
robotics.
This poster will show a low cost production of 96-
channel plastic micro¯ uidic devices to demonstrate the
application of microtechnical fabrication processes for
high-throughput screening, CE-separation and DNA
analysis.
Glass bottom microplates (96, 384, 1536 well) for
high-resolution imaging and single molecule de-
tection
Andreas Gerlach1, Claudia Kaiser1, Henning Vollert2, Angelika
Bastl2 and Guënther Knebel1, 1 Greiner Labortechnik GmbH,
Frickenhausen, Germany, 2Aventis Pharma GmbH, HTS, Assay
Development, Frankfurt, Germany
Griner Labortechnik and Aventis Pharma (formerly
Hoechst Marion Roussel) have co-developed a full set
of unique glass bottom microplates (96, 384, 1536 well).
The glass bottom plates incorporate high quality optical
glass with a thickness of 150mm bonded to the parent
plate. All plates comply to the standardized microplate
footprint and provide superior quality in applications
where low auto¯ uorescence and optical clarity are re-
quired. At the time, these plates are available in opaque
black for high-resolution imaging, sensitive ¯ uorescence
and confocal microscopy applications, like FCS and
single molecule detection.
This poster will focus on the impact of the most relevant
features of glass bottom plates vs. plastic clear bottom
plates and will demonstrate the superior performance in
selected applications.
Ultra-fast dispensing for HTS in high-density
plates
Don Rose and Tom Tisone, Cartesian Technologies, Inc., Irvine,
CA
As 1536 becomes more widely used for high throughput
screening (HTS) applications, there is a need for prac-
tical, automated liquid handling solutions for assay
assembly. Assay assembly involves the delivery of a series
of reagents, typically substrates or protein targets, to
1536 well plates. Addition using a 96-well pipetting
station is extremely slow. Each of 16 transfers requires
several minutes, which includes an aspirate/dispense to
mix the reagents as well as cleaning or disposal of tips.
This can lead to a total plate ® lling time of as much as 30
minutes.
Non-contact ink-jet type dispensing can deliver nanoliter
volumes of liquid to high density plates. Cartesian’ s
patented nQUADTM technology combines the high-
resolution displacement capabilities of syringe pump with
the high-speed actuating capabilities of a microsolenoid
valve to deliver nanoliter volumes in a non contact
manner to 384, 1536, 3456 well plates.
A major advancement in this area has been the develop-
ment of the proprietary synQUADTM technology which
does rapid, ` on-the-¯ y’ dispensing to the plate, much like
a large volume inkjet printer. This is accomplished by
synchronizing the syringe pump, microsolenoid valve,
and the XYZ positioning system. The advantages of
the synQUAD technology are:
. Speed. A 1543 well plate can be ® lled with 4mL per
well in under 30 seconds. This is up to 60 times
faster that a conventional 96 channel pippettor.
. E‡ cient Mixing. The velocity of the liquid being
dispensed is produces eæ cient mixing of reagents in
the well.
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are independently controlled to allow multiple
reagents to be added rapidly to the plate.
. No Tip Washing. The non-contact dispense
mechanism results in the tips dispensing above the
plate such that the tips never touch the contents of
the well.
. Multimode Dispensing. Reagents can be deliv-
ered by either aspirating from a source or bulk dis-
pensing from a reservoir.
. Dynamic Range. Volumes from 20nL to 20 mL
can be dispensed.
. Precision. Reproducibility of the dispense is on the
order of 2% CV in the microliter range and <10%
CV in the nanoliter range.
This paper will give an overview of the nQUAD,
synQUAD technologies as well as presaent data on
linearity, accuracy, and precision for these diå erent
liquid handling modalities.
Miniaturization technologies for high throughput
biology
Peter Coassin, Aurora BioSciences, San Diego, CA
This talk will summarize Aurora’ s strategy to integrate
Biology with miniaturized automation to enable high
throughput screening and biological research. Speci® c
components of the process will be described, including
micro¯ uidics, detection, sample handling, and bioassay
technology amenable to high density formats. Results
from ultra-high throughput (e.g. >100K samples/day)
assays will be presented. The implications of the in-
creased productivity these systems allow for determining
the functions of genes will be discussed.
The integration of Tecan Gemini software with a
generic machine interface for cherrypicking in the
sample supply process
Andrew Bonner, Lee Chambers, Seb Carey and Neil Benn, Glaxo-
Wellcome R&D, Medicine Research Centre, Stevenage, UK
The liquid handling robots (LHR) used at GlaxoWell-
come’ s Stevenage site for the supply of samples for
screening have been integrated with a generic machine
interface. The advantages of using a common interface
which links the LHRs to corporate sample ordering
system ensures high data integrity and reduces process
and data errors. Operators manage requests by directing
them to particular LHRs, and these are processed using
the generic machine interface.
Within the suite of LHRs, there are a number of Tecan
Genesis RSP systems which are used to cherrypick
discrete samples for secondary screening and projects.
There are requirements for greater ¯ exibility and sub-5ul
dispensing which can be met by using Tecan Gemini
software.
The integration of Gemini software can be achieved by
using an ActiveX driver to pull data, for a selected order,
from the corporate database, via the generic interface.
This data can be converted by the driver into a format
that Gemini can use and piped into Gemini via a named
pipe. Both the method and worktable for the processing
of any order are dynamic and constantly changing as
data is passed between the generic interface and the
ActiveX driver, and between the ActiveX driver and
Gemini.
A ￿ exible approach to automated compound
storage software systems
David Harding, Patrick La¡argue, David Shimmin and Michael
Pollard, RTS Thurnall plc, Manchester, UK
The pressure of increasing demand for compounds from
HTS users and increasing library sizes has caused many
pharmaceutical companies to invest in automated com-
pound storage systems. However, while the main aim is
common, each company has its own requirements. For
example, not only do compound library sizes vary, but so
do screening strategies, storage and distribution strat-
egies. In addition there are some very real constraints
such as physical space and existing IT systems.
Automated extraction of natural products from
plant tissues
Bruce E. Richter, Richard E. Carlson and John L. Ezzell,
Dionex Corporation, Salt Lake City, UT
While high throughput screening (HTS) has been ap-
plied to thousands of compounds produced as part of
combinatorial libraries, there is interest in applying HTS
to the pharmacologically active compounds found in
plant tissues. However, these ` marker’ compounds must
® rst be extracted from the tissues in which they naturally
occur before HTS. The extraction techniques normally
used to remove the marker compounds from plant tissues
require long periods of time and copious amounts of
solvents. In addition, none of these extraction procedures
can be automated. Accelerated solvent extraction (ASE)
has been proven to be eå ective in removing marker
compounds from a variety of plant tissues.
Using ASE, a fully automated extraction workstation,
the extraction of marker compounds from medicinal
plants is completed in about 15 minutes using only 20
to 30mL of solvent. Furthermore, ASE may also be used
to determine pesticides levels in medicinal plants before
processing and packaging. ASE yields of the selected
marker compounds have been shown to be equivalent
to or higher than other methods for the same marker
compounds, while at the same time oå ering signi® cant
economy in time, labor, and solvent use. This system
can extract up to 24 samples without any user
intervention.
Assay development in high density MicroWell
1
plates: use of well geometries, format, surface
modi￿ cation and optical properties to achieve
optimal assay performance
Barbara M. Sullivan, Life Science Discovery Products, Nalge
Nunc International, Naperville, IL
When developing assays in high density, low volume
MicroWell plates, it is important to understand how
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and optical properties aå ect assay performance. Hand-
ling issues such as evaporation control, format compat-
ibility with automation, and determining appropriate
reagent concentrations and cell densities resurface as
basic development points. This presentation is designed
to furnish answers to questions such as: ` Is there a perfect
surface?’ ` Do I even need to consider surface charge in a
homogeneous assay?’ and ` How much can I reduce
reagents and expect reasonable signal to noise ratio?’
and to stimulate a discussion regarding practical issues
surrounding assay development.
Information to be discussed was developed in the Re-
search and Development labs at Nalge Nunc Inter-
national (NNI) as well as in collaboration with other
academic and industrial laboratories. We examined
many parameters comparing 96 well plates to 384 well
plates as well as diå erent varities of 384 well plates. Of
note:
. in¯ uence of plate material and surface properties on
assay performance, reagent compatibility and
chemical resistance
. comparison of round and rounded square well geo-
metries and eå ects on liquid cross contamination
. the in¯ uence of surface to volume ratios on the
reduction of reagents, particularly in assays
utilizing modi® ed surface properties
. measurement of cell viability and proliferation
. optimal choice of solid and optical bottom plates as
well as the utilization of pigmented black and white
plates for radioactive, luminescent and ¯ uorescent
assays
. control of mechanical processes, timing the addition
of reagents, and the control of evaporation to opti-
mize the use of high density plate in high through-
put assays
Typically made of polystyrene or polypropylene, Micro-
Well assay plates usually consist of a de® ned array of
round or squared wells. We compared the eå ect and
performance of round and rounded square well geome-
tries on typical assays. Square well plates often had
problems with cross contamination, whereby liquid from
one well would ¯ ow to adjacent wells by capillary action.
Rounded square wells, in conjunction with the plate
material utilized, eliminate capillary action and conse-
quential cross contamination.
Surface modi® cation such as cell culture treatment and
high binding surfaces oå er distinct advantages for speci® c
assays capable of utilizing the solid phase. The two-fold
higher surface to volume ratio in a 384 well plate
compared to a 96 well plate results in signi® cantly higher
signals for assays utilizing surface properties.
Consequently, reagents can be reduced at a ratio greater
than 1:4 while still providing signals comparable to those
achieved in a 96 well plate.
With regard to optical properties, solid black and solid
white as well as back or white optical bottom plates
(OBP) were compared by measuring ¯ uorescent and
re¯ ective properties, signal to noise ratios, light cross talk
and sensitivity. White plates had greatest re¯ ectivity and
lowest background noise particularly for radioactive and
lumininescent assays. Black optical bottom plates were
superior for ¯ uorescent assays when utilized with bottom
reading instruments, showing the lowest background
signal and light scatter, resulting in the highest signal
to noise ratio.
Other considerations are also important for optimal
performance in high density plates. Mechanical pro-
cesses, dispensing, reading and timing as well as control
of evaporation have to be controlled in order to minimize
assay variability.
Second generation, HETM (high e‡ ciency) micro-
plates in 96 and 384 formats: low volume assays
aren't just for 1536 anymore
Amer El-Hage, Jon Petersen, Robert Danielzadeh, Meng
Zhang, Doug Modlin and Mike Biros, LJL Biosystems,
Sunnyvale, CA
Traditionally, there are two primary advantages to
migrating to 1536 well formats: assay volume reduction
and increased throughput compared to lower density
microplate formats. LJL has developed a second-genera-
tion HETM microplate in the 96 and 384 well format that
provides similar reagent, target and compound savings
compared to the 1536 well format. HE microplates, when
used in conjunction with SmartOpticsTM enabled instru-
ments such as AnalystTM, deliver similar sensitivity and
signal to background across a broad range of assay
volumes (4 to 40 microliters). This enables researchers
to develop assays in volumes amenable to hand-pipetting
and then scale down with automated pipettingÐ all
without changing instruments or plates. Several assays
will be demonstrated with this microplate, including
Serine/Threonine Kinase and cAMP monitoring in a
homogeneous HEFPTM format. The HE microplate de-
sign, fabrication and quality control methods provide a
low auto-¯ uorescence background, tight plate-to-plate
uniformity, and lot-to-lot consistency. These attributes
are essential for low volume assay scalability and reliable
HTS automation.
Solving the MALDI-TOF-MS automation puzzle
Claus Koëster, Bruker-Daltonik GmbH, Bremen, Germany
In recent years matrix-assisted laser desorption/ioniza-
tion time-of-¯ ight mass spectrometry (MALDI-TOF-
MS) has grown rapidly in its importance in the areas of
Genom and Proteom research. The method is based on
the laser desorption/ionization of a crystallized mixture of
analyte/matrix (MALDI) by a short laser pulse. The ions
are accelerated inside an electrical ® eld to give all ions
the same kinetic energy, which is equal to _ m/zv2, where
m/z is the mass-to-charge ratio and v the ion velocity. By
measuring the time-of-¯ ight (TOF) between the laser
pulse and the event when the ions hit the detector, m/z
can be calculated. The received average mass spectrum
has a high information content and can be acquired in a
few seconds. Another reason for doing MALDI-TOF-MS
is the possibility of fully automated processing.
But, how to solve the puzzle of creating fully automated a
mass spectrum from a real sample?
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(2) Do parallel processing (8 needles or more, MAP II/
8).
(3) Be ¯ exible and use Excel and it’ s macrolanguage
Visual Basic to run the liquid handler.
(4) Use magnetic bead clean up.
(5) Reduce your sample volumes to sub-microliter
amount but not lower.
(6) Prepare the sample on a microwell plate MALDI-
target (SCOUT MTP).
(7) Use the anchorchip technology.
(8) Use fuzzy-logic and/or visualization software to
create a MADLI-TOF-MS.
(9) Use a non-gritted TOF-MS to increase sensitivity
and non-disturbed sample picture.
Con￿ uent sample analysis for ultra high-through-
put screening
Kerry G. Oliver, Luminex Corporation, Austin, TX
Multi-Analyte Pro® ling using suspension arrays is a well
established method for increasing throughput while
decreasing costs and sample size. The attendee will now
learn how to use the Luminex technology to perform
ultra high-throughput screening for enzymatic, antigen-
antibody, and nucleic acid based applications. The
inexpensive system is capable of analyzing 32,000 micro-
titer wells per day. Multiplexing just 10 analytes per well,
the total throughput of a single system is over 300,000
analyses per day. Sensitivity and precision will be
demonstrated which equals or surpasses any current
system. Techniques for working with kinases, single
nucleotide polymorphisms, and expression analysis will
be presented.
Automated massively parallel high-throughput
screening using a unique SPE ‘Card'
Robert Pranis and Jason Jacobson, 3M Filtration Products-
Empore, Mendota Heights, MN, John Janiszewski, Mark Cole,
P¢zer, Groton, CT Tom Astle, Tomtec, Hamden, CT
The explosion of new drug synthesis via combinatorial
chemistry has generated incredible pressures on the
analytical chemist to evaluate and analyze tens of
thousands of new compounds a year via in vitro tests
coupled with SPE and LC/MS. This has led to novel
methods for coping with the large numbers of samples. A
joint venture between P® zer, 3M and Tomtec has
produced such a method to rapidly screen samples using
Empore technology in a unique ` card’ format compatible
with existing automation equipment.
The Empore SPE Card is a high-throughput screening
disposable used to shorten the lead drug candidate
selection process by providing parallel chromatography
and direct injection into a LC/MS system from the card.
The card has the footprint of a 96 well micro-titer plate
and has 96 elution zones. Automated activation, loading
and washing steps were accomplished utilizing a modi® ed
Tomtec Cell Harvester. Direct injection of the drugs into
the mass spectrometer was accomplished by elution
utilizing a prototype device. Versatile, easy-to-use soft-
ware provides powerful synthesis control along with
extreme simplicity.
High-speed 96-well format oligonucleotide synthe-
sizer
Damien Luk, Robert D. Guettler, Jimmy Koh, Anh Tuyet-Doan
and Aaron Schohn. GeneMachines, San Carlos, CA
Oligonucleotides are essential elements of genomic re-
search. The PolyPlexTM oligonucleotide synthesizer
makes 96 diå erent oligos in standard 96-well format,
which is amenable to downstream high-throughput pro-
cessing and handling. Operator time is minimal and
synthesis time is less than 3 hours for a 96-well plate of
20-mers. By eliminating ¯ ushing of reagent lines through
a parallel dispensing technology, optimal synthesis time
and reagent consumption are achieved. PolyPlex’ s low
reagent consumption generates oligos quickly, at low
costs and small scales as low as 10nmol. Synthesis costs,
including all consumables, are less than $0.10 per base.
The PolyPlex synthesis chamber provides an inert-gas
environment where synthesis progress can be monitored
by using full-plate trityl collection after any base addi-
tion. PolyPlex utilizes fully licensed chemistry and gen-
erates oligos with greater than 98% coupling eæ ciency.
Versatile, easy-to-use software provides powerful syn-
thesis control along with extreme simplicity.
Micro-centrifugation for small volume nucleic
acid sample preparation: an e´ ective, cost-saving
technology
Nancy Bergsteinsson, Ben Riepe, Anthony Matero, Tad Finkler,
Melinda Au, Poonam S. Medberry and Carl U. Buice.
GeneMachines
1, San Carlos, CA
The newest generation of capillary sequencers has chal-
lenged the capacity of current sample preparation tech-
nologies. As researchers prepare millions of samples for
squencing, they are required to prepare large numbers of
samples, and are faced with steep costs. We have devel-
oped and tested a new centrifugation technology that
hopes to address these problems in sample preparation.
The GeneMachines
1 Array Centrifuge is a novel ap-
proach to centrifugation, to any preparation technique
requiring separation. It arrays 96 individual rotors, each
a vessel for both centrifugration and sample processing,
which spin up to 14,000g. The integration of this unique
centrifuge into a liquid-handling platform creates our
RevPrepTM workstation for automating standard proto-
cols, in an unattended, high-throughput manner. The
rotors enable drastically decreased centrifugation times,
increased throughput and reduced costs.
We will show how the Array Centrifuge impacts various
protocols, including plasmic preps, BAC preps and PCR
product clean-up, by explaining the technology and
results from the RevPrepTM.
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31High throughput synthesis, deprotection, puri￿ ca-
tion and analysis of ribozymes
Mark Sanseverino, Lara Maloney, Laurent Bellon, Kuyler Jones,
Bryce Keen, Victor Mokler and Leonid Beigelman, Ribozyme
Pharmaceuticals, Boulder, CO
Cell culture-based primary screens of a large number of
ribozymes is a critical component of the accelerated drug
discovery program at RPI. In order to produce the
necessary ribozymes in a high throughput manner RPI
has reformatted and automated the olignucleotide
production process to a 96-well-based format. This
poster exempli® es the solutions selected for each of the
four integral components of the ribozyme production
process; Synthesis, Deprotection, Puri® cation and
Quality Control/Analysis.
The 96-well format in tandem with the workstation
platform allows a rapid and well-controlled production
of ribozymes. This production process has the capacity to
produce 2000 oligonucleotides per month under its
current con® guration.
Evaluation of 384 kinetic assays as a screening
platform
Christine Ladislaw, Cameron Stuver and Mark Namchuk, Vertex
Pharmaceuticals, Cambridge, MA
The use of data obtained from one drug development
program to gain an advantage in a subsequent project is
a longstanding goal of the pharmaceutical industry. This
concept is best illustrated when families of related targets
are being pursued (kinases, GPCR’ s, etc.) where the
ability to predict selectivity issues early on has tremen-
dous practical bene® t. It is also a centerpiece for the
Vertex Chemogenomics initiative. In order to generate
large quantities of HTS data of suæ cient quality for this
type of analysis, we have developed a 384 kinetic enzyme
assay platform for kinases using a standard coupled
enzyme assay. Automation consists of standard Zymark
robotics platform upgraded with a pair of Hypertask
quadrant positioners. Development issues particular to
small volume kinetic assays are discussed. One of the
clear bene® ts of screening kinetically is low false positive
rates. Approximately 70% of the compounds we observe
as hits, with this method provide demonstrable dose
responses when retested with fresh samples of the com-
pounds. Other bene® ts are discussed below.
An e‡ cient and fast procedure for the Hantzsch
dihydropyridine syntheses using microwave
based coherent synthesisTM
Jacob Westmana and Liselotte O ë hbergb, aUppsala, Sweden,
Personal Chemistry AB, bUppsala, Sweden
The preparation of 1,4-dihydropyridines by classical
Hantzsch synthesis,1 a one-pot condensation of an alde-
hyde with alkyl acetoacetate and ammonia was devel-
oped more than hundred years ago. In the forties the
interest for this substance class increased due to their
pharmacological activity.2 4-Aryl-1,4-dihydropyrdines
form an important class of calcium channel antagonists.3
When sterically hindered aldehydes are employed in
classical Hantzsch synthesis, long hours of re¯ ux are
needed, but still the yields are generally low.4;5 Reactions
assisted with microwave dielectric heating usually gives
shorter reaction times and often higher yeilds compared
to conventional methods6 and has lately become a
popular method. In order to evaluate the possibility to
increase the yield we used a Smith SynthesizerTM from
Personal Chemistry, a mono-mode microwave synthe-
sizer with both temperature and pressure control.
With the use of Smith Synthesizer we here show that
Coherent Synthesis are a rapid method compared to
conventional heating for producing high yielded library
synthesis of 1,4-dihydropyridines. We also shown that
due to the temperature control provided by the Smith
SynthesizerTM, time and temperature could be varied
independently of each other, which made it possible to
increase the yield for this typical substance class com-
pared with both conventional methods and the use of
domestic microwave ovens.
1 Hantzsch, A., Justus Liebigs Ann. Chem, 215, 1882, 1± 82.
2 Goldmann, S., Stoltefuss, J., Angew. Chem. Int. Ed. Engl., 30, 1991,
1559± 1578.
3 Di Stilo, A., Visentin, S., Clara, C., Gasco, A. M., Ermondi, G.,
Gasco, A., J. Med. Chem, 41, 1998, 5393± 5401.
4 Loev, B., Goodman, M. M., Snader, K. M.,Tedeschi, R., Macko, E. J.,
J. Med. Chem, 19, 1974, 956± 965.
5 Kuthan, J., Palecek, K., Collection Czechoslov. Chem. Comm., 39, 1974,
3711.
6 Majetich, G., Hicks, R., Res. Chem. Intermed., 20(1), 1994, 61± 77.,
Strauss, C. R.,Trainor, R.W., Aust. J. Chem., 48, 1995, 1665± 1692.,
Caddick, S., Tetrahedron,, 36(11), 1995, 10403± 10432.
A new concept for the on-line storage of sample
plates, integrated with plate preparation for high-
throughput screening and ‘cherrypicking'
Jacques H. M. van den Broek, Will H. A. Kuijpers and Thijs
de Boer, NV Organon, Oss, The Netherlands; and Jonathan H.
Connick, Organon Laboratories, Newhouse, UK
Recently Organon installed automated screening and
plate preparation systems for its research facilities in
Oss (The Netherlands) and Newhouse (UK). These
robotic systems have been developed in close collabor-
ation between Organon and Scitec Laboratory Auto-
mation (Lausanne, Switzerland).
Each of the systems consists of three linear track robots,
one of which performs the screening process using
standard peripherals. The other two robots take care of
the plate preparation and ` cherrypicking’ procedures. To
this end, copies of our total mother plate collection are
stored under controlled conditions in Scitec plate stackers
(AutoStack) that can be addressed by one of the two
robots. The system is designed in such way that the
loading and refreshment of the on-line storage,
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executed automatically in 24 hours operation.
A more detailed design of the system and the rationale
behind it will be further disclosed.
Evaluating the performance and capacity of an
MTP and microtube Storage Facility
Thorsten Poëtter*
#, Frank Boëhme*, Olaf Brackhagen*, Frank
Marciniak*, Wolfgang Roëben*, Hermann Stein* and Otto
Ramsebner{
By deciding to extent the screening cascade in the
agriculture business unit of Bayer AG by implementing
High Throughput Screening we were confronted by
many questions:
. How will we screen in HTS mode?
Ð single compounds vs. mixture
Ð plate formats
Ð throughput
. How to validate ® rst screening information?
Ð retest
Ð dose response information
Ð other tests
. How to store the compounds?
. liquid vs. solid
. frozen or not
. How to provide compounds?
Ð ready to use or not
Ð volume and concentration
In answering these questions it became obvious that we
had to design a new storage system to support two new
HTS-robots and several workstations. We decided to
screen single compounds in a 384 plate format and to
validate HTS-hits by dose response information. Com-
pounds should be provided more or less ready to screen as
DMSO solutions, therefore several copies must be stored
in MTPs and Microtubes (384 tubes on a rack with MTP
footprint). For quality reasons these solutions should be
frozen and the number of freeze/thaw cycles should be
limited. These assumptions, the expected number of tests
per year and the size of the library were used to estimate
the capacity and the desired throughput of the storage
system.
Meanwhile a REMP system with capacity of more than
130,000 storage positions is in place and we have been
able to measure exact movement times of the robot and
access times to the MTPs and Microtubes.
Depending on our assumptions the throughput varies,
especially for the Microtubes. With the same equipment
the output of tubes per hour ranges from 88 tubes/hr to
more than 1000 tubes/hr. The input/output of MTPs
varies only from 91 to 162MTPs/hr. The poster shows in
detail how these results were compiled.
*Bayer A G, Crop Protection Business Group, D-51368 Leverkusen,
Germany.
{Remp A G, Laboratory Automation, Oberdiessbach, Switzerland.
Automated ￿ ow system for the reformatting and
dispatch of screening samples in duplicate vials
David Jacobs, Oxford Asymmetry Int., Oxford, UK
Oxford Asymmetry International is a provider of sophis-
ticated chemical services to the pharmaceutical, agro-
chemical and biotechnology industries. The Discovery
division prepares multiple compound libraries for both
lead discovery and lead optimisation. These compounds
are reformatted prior to dispatch so they can be seam-
lessly incorporated into our clients’ compound archives,
requiring diå erent reformatting procedures to be used for
each client.
The collaboration in question required the synthesis,
analysis, reformatting and dispatch of 200,000 com-
pounds over a 2-year term. Each sample was transferred
from microtitre plates into duplicate vials and the weight
of material in each vial accurately determined.
This poster will highlight the processes involved in the
reformatting of these ¹200K screening samples using the
Zymark XP weigh station and Gilson 215 liquid hand-
lers. It describes the handling and transfers of samples
and indicates the amount of data generated both elec-
tronically and in hard-copy format.
This presentation will demonstrate the direct impact of
laboratory automation in delivering large numbers of
combinatorial samples.
The whole process routinely dealt with ¹9K com-
pounds/month and this poster will highlight the role
the Zymark XP robot weigh stations played.
Use SciClone with robotic system to perform
multiple assays and assay optimization
Randy Yen, John Hanson and Wai Lee Wong, Assay &
Automation Technology Department, Genentech, Inc., South San
Francisco, CA
We have set up a few ORCA and CRS robotic systems to
handle the high throughput screening assay, but there
are still a lot of regular assays needs to be run by analyst
manually, because those are not for high throughput
screening, so the samples amount are low. It is not good
to put on the robotic system. To automate those assays
eæ ciently, we decide to modify our robotic system with
SciClone station to handle those assays at the same run
by continuing using Clara LT scheduling software and
without changing the current hardware setting.
The Clara LT scheduling software usually handle one
assay at a time, but by using SciClone station, we are
able to run multiple assays at the same time. We have
taken an advantage of SciClone ActiveX communication
to develop our own DDE SciClone driver to handle the
activity between the robot system and SciClone station.
It gives us the ¯ exibility to use SciClone with the ORCA
robotic system eæ ciently. Beside enhance the commu-
nication for the system, we have to improve the sample
tracking method for our robotic system, so we are able
to handle multiple assays in one robotic system and use
the robot as a assay develop tool to for the assay
development.
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those assays have the same incubation time and devel-
opment time and then batch them together in one run, so
Clara LT will treat all of them as one assay. Second, we
need to program the robotic control software to track the
sample number and identify which reagent should be
used for each sample then the program will instruct the
SciClone station to treat them as a diå erent assay and
pipette proper reagent to each plate. By this way, analyst
can combine several diå erent assays run in one robotic
run. The robotic system will run all of them at once
without trouble.
b. To optimize an assay: We use all the position on the
SciClone deck to setup several diå erent reagents and
leave one position for tips box. By using our new
program, robot can instruct SciClone to pipette proper
reagent to the associated sample plate. In one run.
Analyst can test several diå erent reagents at once. It
can be used to optimize the assay quickly and speed up
the assay development for scientist.
Automated antibiotic susceptibility assays
Ken Coleman1, Randall Engler2, Stewart Pearson1 and Eudell
Swann1, 1SmithKline Beecham Pharmaceutical Research,
Collegeville, PA 2Kendro Laboratory Preoducts, Newtown, CT
Standard antimicrobial susceptibility testing typically
requires 18± 24 h incubation of organism in a range of
antimicrobial concentrations before a growth reading is
taken and used to determine the Minimum Inhibitory
Concentration (MIC) of the drug.
For high-throughput assays, where large numbers of
compounds are screened and few are expected to be
active, a single, high concentration of agent can be used
and hits then progressed to a full MIC assay, with a
saving of time, labour and compound. The sensitivity of
this assay can be increased by taking readings at inter-
mediate times, such as 8 & 16h, making it possible to
identify (1) Agents whose MIC is 2± 8£ higher than the
working concentration (2) Active agents which are
breaking down over time.
Both types of assay have been successfully automated
with the integration of an Heraeus cytomat
TM 6000 in-
cubator (Kendro, Newtown, CT), two Microlab AT2 Plus
plate processors (Hamilton, NV), a Multiscan Ascent
plate reader (Labsystems, MA) and an R16 tracked
robot (ST Robotics, NJ), using the Overlord procedural
language (Process Analysis and Automation, UK).
Just-in-time compound delivery to multiple kin-
ase targets for concurrent speci￿ city screening
Brent Butler, Cole Harris, Stephanie Schweiker and Edgar
Wood, Molecular Biochemistry Department, Glaxo Wellcome
Inc. Research Triangle Park, NC
We have developed a simpli® ed method for serially
diluting and delivering compounds to multiple sets of
assay plates. This has permitted us to concurrently screen
large numbers of compounds against multiple kinase
targets in a just-in-time manner. The data generated in
these screens allows us to quickly and reliably determine
the potency and speci® city of kinase inhibitors.
Use of laboratory automation in the drug discov-
ery groups
Joseph A. Short, Thomas L. Lloyd and Eric D. Lynch, DuPont
Pharmaceuticals Company, Newark, DE
The use of laboratory automation in our discovery group
has drastically increased the throughput of test com-
pounds. Of the diå erent kinds of lab automation in our
department, our discovery group uses three types: The
Zymark PyTechnology robot, Packard MultiProbe II
and Tomtec Quadra96 SPE Workstation. The Zymark
robot was one of the ® rst pieces of lab automation used in
our group. It is used for completing serial dilutions for
standard and quality control samples. It is also used for
solid supported liquid/liquid extractions (Chem Elut)
and on-line protein precipitation extractions. The Pack-
ard MultiProbe and Tomtec Quadra96 are liquid hand-
lers, used primarily for solid phase extraction using 96
well microplates. The use of these tools in our drug
discovery group will be presented and discussed.
Fully automated anti-varicella Zoster enzyme-
linked immunosorbent assays supporting manu-
facture of a novel intravenous therapeutic for
treatment of aliments caused by the Varicella
Zoster Virus
LeeAnne Macaulay, Andrea Masi, Lori Soluk and Danuta
Kierek-Jaszczuk, Cangene Corporation, Winnipeg, Manitoba,
Canada
A novel liquid-based therapeutic VZIG has recently been
developed at Cangene, which specializes in the manu-
facture of human plasma-based pharmaceuticals. The
manufacture of this pharmaceutical is supported by two
VZV ELISAs, a commercial Wampole Laboratories
VZV IgG ELISA
1 and an in-house developed, ampli-
® ed antibody-capture ELISA, which were validated for
the quantitation of the Varicella Zoster Virus speci® c
antibodies in the ® nished product and patient sera,
respectively.
The purose of the present studies was to impove and
streamline the performance of the assays by automating
several procedural steps that are of a crucial importance
for the ELISA performance. The ATplus 2 Liquid
Handler, working in tandem with the Microlab
F.A.M.E. Plate Analyzer were used to automate: (i)
the preparation and pipetting of serial dilutions in 96-
well microtitre plates, and (ii) downstream processing of
the plates. The plate-processing steps included incuba-
tion, plate washing, reagent addition, photometric read-
ing as well as data capturing and management. All liquid
handling and plate-processing steps were pre-pro-
grammed using the software of the respective Microlab
instrument. The designed and programmed protocols
closely followed the procedures detailed in the Standard
Test Methods for the validated commercial Kit and in-
house ELISA and incorporated the steps allowing for a
positive identi® cation of the processed microplates.
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multiple plate experiments. After serially diluted samples
were automatically prepared and pipetted into 96 wells
of the microtitre plates, the plates were inserted into the
F.A.M.E. for further processing in accordance to the
programmed protocols. On the conclusion of the experi-
ment, a printout with the raw and blank reduced data
was obtained and the data was graphed and analyzed
using the Excel spreadsheet program. It has been shown
that both automated ELISAs were capable of accurate
and reliable quantitation of the anti-VZV antibodies
from standardized preparations. This proves that both
VZV ELISAs can successfully be performed, in a fully
automated manner, on the platform oå ered by the
Microlab instruments. The automated ELISAs oå er an
advantage of the increased data security and traceability
as well as reduction of human error.
Automated plasma protein binding screen:
implementation on a Tecan Genesis and Zymark
RapidPlate
1
Kelly Jordan, Jimmy Bruner, Cosette Serabjit-Singh and Stephen
A. Wring, Glaxo Wellcome Inc., Research Triangle Park, NC
Drug binding to plasma proteins can markedly aå ect
disposition, and early information on binding could
aå ord more rapid drug design and selection. Unfortu-
nately, established methods for determining plasma bind-
ing are not amenable to drug discovery as they are
laborious and not readily automated.
To improve throughput we have developed an auto-
mated method employing a novel 96 well ultra® ltration
format, with a Zymark RapidPlate
1 and a Tecan
Genesis 150, that increases capacity 4 fold to 32 com-
pounds per run.
The RapidPlate
1prepares analytical standards in drug-
free plasma and ultra® ltrate, and also spikes test plasma.
After incubation, the Genesis transfers the incubated
plasma samples to a Millipore Microcon ultra® ltration
plate that is centrifuged to produce ultra® ltrate. The
Genesis then collects the ultra® ltrate and the Glaxo
Wellcome Balance Data Collection system determines
the volume produced. The Genesis uses the volume data
to restore plasma retentate back to its starting volume by
addition of drug-free ultra® ltrate. Drug concentrations
are determined in ultra® ltrate and plasma retentate
samples, thereby allowing calculation of the bound
fraction (Fb) and mass balance.
The method has been applied to an evaluation set of
compounds and data show good agreement with litera-
ture values of Fb over the range of 10± 99.5%.
High-throughput screening based on multiplexed
CE and absorption detection
Edward S. Yeung, Xiaoyi Gong, Lianjia Ma, Seong Ho Kang
and Yonghua Zhang, Ames Laboratory-USDOE and Department
of Chemistry, Iowa State University, Ames, IA
Capillary electrophoresis (CE) is now a mature technique
for analytical separations. In its various modes, impress-
ive performance has been demonstrated for ionic as well
as for neutral compounds. The Human Genome Project
provided the impetus for developing multiple capillary
systems. However, capillary arrays are not just for DNA
analysis. Every CE protocol can be similarly multiplexed
to achieve higher throughput and reduced reagent con-
sumption without sacri® cing its good resolving power
and full automation. To extend the applicability to
non-¯ uorescing compounds, we constructed a simul-
taneous multiplexed absorption detector for 96 capil-
laries. Entire sample trays in the 96-well microtiter
plate format can be analyzed in one operation. This
high-throughput capability gives CE a unique advantage
over column liquid chromatography in most applica-
tions. Examples from DNA analysis, enzyme assay,
peptide mapping and combinatorial synthesis will be
presented.
The determination of membrane a‡ nity using
solid supported lipid bilayers (Transil
1)-lipo-
philicity in high-throughput processes
T. Hartmann, M. Schoëttner and A. Loidl-Stahlhofen, NIM-
BUS Biotechnology GmbH, Leipzig, Germany
Quanti® cation of lipid binding performance of pharma-
ceuticals is very important in pharmacology, medicine
and biochemistry. The huge amount of new compounds
generated by combinatorial chemistry requires a quick
and automated lipophilicity assessment. In case of phar-
maceuticals the octanol-water partition coeæ cient o/w is
a popular descriptor of the pharmacokinetic behavior in
biological systems. Nevertheless, whenever surface active
and/or charged compounds are to be investigated, the
Po/w is prone to fail as the bulk phase octanol is unable to
mimic the anisotropic membrane behavior. Therefore
membrane model systems are often applied for quantify-
ing membrane aæ nity. Usually, they achieve a better
correlation, but show severe drawbacks especially due to
the enormous expense of time needed for data acquisi-
tion. We develop a new process for the high-thoughput-
screening of lipid/water partition coeæ cients (Plipid/
water) to overcome the limitations of Po/w: Solid sup-
ported lipid bilayers (TRANSIL
1) combined with
HPLC-technique allow a fast, easy and reproducible
determination of membrane aæ nity (lipophilicity).
TRANSIL
1, a new tool for functional immobiliza-
tion of transmembrane proteins by lipid bilayers
on a solid support for high-throughput processes
J. Noeller, J. Schmitt and S. Kaufmann, NIMBUS Biotechnol-
ogy GmbH, Karl-Heine StraÞe 99, D-04229 Leipzig, Germany
Rational design of new drugs requires a fast and reliable
access to their interaction properties with cellular mem-
branes such as (i) binding to the target proteins (ii) drug
targeting, membrane aæ nity, and permeation. Here,
solid supported lipid bilayersÐ with or without immo-
bilized membrane proteinsÐ are of key interest in the
® elds of pharmaceutical screening, biosensors and bio-
separation. Their major advantage is improved long
term stability and greater ease of handling as compared
to systems without support i.e. vesicles, cells or pro-
teoliposomes. TRANSIL
1, a new surface consisting of
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investigation of transmembrane proteins (like GPCR-
proteins) in the ® elds of pharmaceutical screening and
biosensors. To mimic cellular membranes, TRANSIL
1is
optimized in regard to lipid composition and bilayer-
support interactions. Therefore, transmembrane proteins
are readily immobilized in a matrix similar to their
natural environment, showing no signi® cant loss of
activity and even preferred orientation. In combination
with state-of-the-art detection tools, this versatile system
is very suitable for the assessment of ligand binding,
protein-protein interactions and general functional
studies of receptors and transporters or other transmem-
brane proteins.
Fast synthesis at the Janssen research foundation
Davy Petit, Marc Schroven, Janssen Research Foundation,
Beerse, Belgium
This poster gives an overview of how parallel synthesis is
performed in the Fast Synthesis Lab, a subunit of the
combichem group at the department of medicinal chem-
istry. The entire work¯ ow and data¯ ow are automated.
A Zymark robot is used for lab-intensive manipulations.
An automated preparative LC/MS puri® cation system
delivers compounds with a minimum purity of 90% at an
average yield of 50mg. A high throughput analysis tool
determines the purity of the compounds based on MS
and UV data. Data handling (calculations, registra-
tion,...) is accomplished using MS Excel, Accord Com-
bichem and Accord for Excel.
An electrochemiluminescence-base d assay for
cAMP
Tamyra Shafer, Jim Schmidt, James W. Karaszkiewicz and
Elizabeth Kenten, IGEN International, Inc., Gaithersburg, MD
Cyclic adenosine monophosphate (cAMP) is generated
by cells in response to the activation of certain G-Protein
coupled (GPC) receptors. Increases in the levels of
intracellular cAMP aå ect a wide range of cellular pro-
cesses. The measurement of cellular cAMP levels is an
important tool in basic studies of G-protein coupled
receptors, and screens for compounds that aå ect GPC-
receptor function. We describe an ORIGEN
1assay that
measures intracellular cAMP using a competitive immu-
noassay format. The procedure combines the lysis of the
cellular samples and the competitive binding reactions
into a single incubation step; reagents may be added
directly to cells in microwell plates.
Products of the immunoassay binding reactions are
quantitated by electrochemiluminescence detection using
ORIGEN
1 instrumentation such as the M-SeriesTM
M-8 Analyzer. The cAMP assay has a detection limit
of less than 10 pmol/ml and a wide dynamic range
extending to concentrations greater than 1,500pmol/
ml. The protocol is simple, does not require sample
pretreatment or wash steps and lends itself well to
automation. Acetylation of cAMP is not required. The
ORIGEN cAMP assay illustrates the usefulness of elec-
trochemiluminescence detection for the measurement of
analytes in complex matrices such as cell lysates.
Corning 1536-well assay plate for HTS
Arthur Trombley, Corning Inc. Science Products Division, Ports-
mouth, NH; Jill Veilleux, Corning Inc. Science Products
Division, Action, MA; David Dunn and Marc Orlowski,
Pharmacopeia, Inc., Princeton, NJ; Meng Zhang and Doug
Boyd, LJL Biosystems, Inc., Sunnyvale, CA
The new Corning 1536-well 2ml Plate provides the
foundation for a unique solution to assay miniaturization
for high throughput screening. The advantages of the
1536-well HTS plate include:
(1) Conservation of 96 and 384 well format, which aids
in sample transfer, well identi® cation, and data
manipulation.
(2) Low pro® le, which provides increased sample density
over conventional plate height and reduces parallax
eå ects in imaging systems.
(3) Three point positioning and tight manufacturing
tolerances for all dimensions, which enable high-
speed automated plate handling functions.
(4) The lowest volume wells (2ml) that are commercially
available.
(5) Optimized materials for manufacture, which en-
hance performance in ¯ uorescence, luminescence
and colorimetric detection formats.
Here, we probvide an analysis of evaporative loss,
automated dispensing at low volumes, coupled to detec-
tion of luminescent substrate. The Corning 1536-well 2ml
Plate is shown to be an ideal solution to scale up from
traditional 96 and 384 well formats in high throughput
screening applications.
Fluorescent cell based assays for high throughput
analysis
Jeanne Phillips and Aldo Pitt, Millipore Corporation, Danvers,
MA
Ideally suited for high throughput applications, cell
based ¯ uorescent and time-resolved ¯ uorescence (TRF)
assays are typically less expensive and hazardous than
radioactive assays and are versatile, sensitive, and quan-
titative. Common uses include detection of cell-cell
adhesion, cell viability, proliferation, cell cycle determi-
nation, apoptosis as well as detection of speci® c proteins/
receptors.
In our present study, we determined the incorporation of
a ¯ uorescent probe precursor (calcein AM) by measuring
intracellular ¯ uorescence both in suspension and in
adherent cell lines. Calcein AM is cleaved by intracel-
lular esterases to form calcein, a pH-independent, cyto-
solic ¯ uorescent marker. Calcein AM uptake was
measured in cyclosporin or verapamil inhibited P-glyco-
protein (Pgp expressing MDCK and MES-SA/MX2)
cells. The MultiScreen
1-PCF and FL plates possess some
highly desirable features for automated high-throughput
cell based ¯ uorescent screening procedures. In addition
to culturing the cells, all the subsequent assay steps (such
as media exchanges, drug treatment, washing, and read-
ing) can also be performed directly in the same Multi-
Screen plate with a signi® cant reduction in process time.
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throughput plasmid puri￿ cation system
Michael J. Domanico, Jamie L. Noble, Natalie Y. Trees,
Joseph A. Hensley, Preston B. Hradecky, Kelly M. Clark and
Randolph J. Hellwig, Eppendorf-5 Prime, Inc., Boulder, CO
The PERFECTprep automated plasmid puri® cation
system proved to be very reliable and robust both in
internal and external validation studies. The system was
rigorously tested internally by performing 4800 puri® ca-
tions per day for two weeks. As part of the platform
installation process, 9600 puri® cations were also per-
formed at each of three genome sequencing centers. A
total of six host/vector combinations were utilized to
demonstrate product reliability and consistency within
diå erent cell types.
Agarose gel analysis revealed excellent reproducibility
and uniformity of the puri® ed plasmid, with yields of
100 ng/mL in more than 90% of the preps. The
DNA sequencing quality averaged 475 base pairs of
PHRED Q20 for the entire validation study. These
results conclusively demonstrate that this plasmid
puri® cation system is robust and capable of pro-
ducing sequencing quality plasmid in a high throughput
mode.
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